 
Page 1 of 84  
Pancreatic Cancer Radiotherapy Study Group (PanCRS) Trial:   
A Randomized Phase III Study Evaluating Modified FOLFIRINOX 
(mFFX) with or without Stereotactic Body Radiotherapy (SBRT) in 
the Treatment of Locally Advanced Pancreatic Cancer  
 
 
 
 
Coordinating C enter  
Stanford Cancer Institute  
875 Blake Wilbur Drive  
Stanford, CA 94305  
 
Protocol Director/Principal Investigator  
Daniel Chang, MD  
Department of Radiation Oncology  
875 Blake Wilbur Drive, MC 5847  
Stanford, CA 94305 -5847  
 
 
  
Co-Principal Investigators  
MD Anderson  
Albert Koong MD, PhD  
Chair of the Department of Radiation Oncology  
1515 Holcombe Blvd, Unit # 1422  
Houston,TX 77030  
 
Joseph M. Herman MD., M.Sc  
Director of Clinical Research  
Department of Radiation Oncology  
1515 Holcombe Blvd, Unit # 1422  
Houston,TX 77030  
 
 
 
 
 
Co-Investigators  
George Fisher, MD, PhD  
Medical Oncology  
875 Blake Wilbur Dr., MC 515 1 
Stanford, CA   94305 -5826  
 
 
 

  
Page 2 of 84 
 Pamela Kunz, MD  
Medical Oncology  
875 Blake Wilbur Dr.  
Stanford, CA 94305  
 
 
 
Jeffrey Nort on, MD  
Department of Surgery  
300 Pasteur Dr., MC 5641  
Stanford, CA   94305 -5641  
 
 
 
George Poultsides , MD  
Department of Surgery  
300 Pasteur Ave.  
Stanford, CA   943 05 
 
 
 
 
Stephanie T. Chang, MD  
Stanford Department of Radiology  
300 Pasteur Drive, Rm H1307 MC 5105  
Stanford, CA 94305  
 
 
 
 
Biostatistician  
Rie Von Eyben , MS  
Department of Radiation Oncology  
Stanford University Medical Center  
875 Blake Wilber Drive, MC 5847  
Stanford, CA 94305  
 
 
 
 
Study Coordinators  
Stanford University Medical Center  
Rachel Freiberg, Ph.D.  
Clinical Trials Manager  
Department of Radiation Oncology  
Stanford University Medical Center  
800 Welch Rd., FC3C69  
Stanford, California 94305  
 

  
Page 3 of 84 
 Email: rachelf@stanford.edu  
 
Samantha Wong  
Clinical Research Coordinator  
Department of Radiation Oncology  
Stanford University Medical Center  
300 Pasteur Drive,  
Palo Alto, CA 94305 -5763  
 
 
 
 
Stritch School of Medicine, Loyola University Chicago  
Tarita Thomas, MD, PhD , Principal Investigator  
Department of Radiation Oncology  
Cardinal Bernard in Cancer Center  
2160 S 1st Ave  
Maguire Center, Rm 2932  
Maywood, IL 60153  
 
 
 
William Small Jr., MD  
Department of Ra diation Oncology  
Cardinal Bernardin Cancer Center  
2160 S 1st Ave  
Maguire Center, Rm 2932  
Maywood, IL 60153  
 
 
 
Sam Pappas , MD 
Depa rtment of Surgical Oncology  
2160 S First Avenue  
Chigaco, IL 60153  
 
 
 
Asha Dhanarajan, MD  
Department of Oncology and Hematology  
Cardinal Bernardin Cancer Center  
2160 S 1st Ave  
 
 
 
Janelle Meyer MD  
Department of Medicine  
Oncology and Hematology  
Cardinal Bernardin Cancer Center  

  
Page 4 of 84 
 2160 S 1st Ave  Building 112 Room 271  
Maywood, IL 60153  
 
 
Gerard V. Aranha, MD  
Department of Surgery  
Division of Surgical Oncology  
2160 South First Avenue  
EMS Bldg. 110, Room 3236  
Maywood, IL  60153  
 
 
 
Gerard J. Abood, MD, MS  
Department of Surgery  
Division  of Surgical Oncology  
Loyola University Medical Center  
 
 
 
Eva M. Wojick, MD  
Department of Pathology and Urology  
Loyola University Medical Center  
2160 South First Avenue  
Maywood, IL 60153  
 
 
 
Swedish Cancer Institute  
Vivek Mehta MD, Principal  Investigator  
Radiation Oncology  
1221 Madison Street  
Arnold Pavilion, 1st Floor  
Seattle, WA 98104  
 
 
Somasundaram Subramaniam , MD MS  
Medical Oncology  
1221 M adison Street, Suite 200  
Seattle, WA 98104  
 
 
 
University of Texas Southw estern Medical Center  
Jeffrey Meyer, MD, MS , Principal Investigator  
Department of Radiation Oncology  
UT Southwestern Medical Center  
5801 Forest Park Road, NF3.206  
Dallas, TX 75390 -9183  

  
Page 5 of 84 
  
 
 
Princess Margaret Cancer Center  
Laura A Dawson, MD FRCPC  
Professor,  Dept. of Radiation Oncology,  
University of Toronto  
Clinician -scientist and staff radiation oncologist,  
Radiation Medicine Program,  
Princess Margaret Cancer Centre  
Toronto, Ontario , CANADA  
 
 
 
Hollings Cancer Center, MUSC  
David T. Marshall, M.D., M.S.  
Professor of Radiation Oncology  
Hollings Cancer Center - A NCI -Designated Cancer Center  
Medical University of South Carolina  
MSC 318  
169 Ashley Avenue  
Charleston, SC 29425  
 
 
 
The University of Texas MD Anderson  Cancer Center  
Albert Koong, M.D.  
Chair of the Department of Radiation Oncology  
The Univ of Texas MD Anderson Ca ncer Center  
1515 Holcombe Blvd, Unit 1422  
Dept of Radiation Oncology Houston, TX 77030  
 
 
 
 
 
 
Stritch  School of Medicine, Loyola University Chicago  
Beth Chiappetta, RN  
Research Nurse  
Loyola University Medical  Center  
Radiation Oncology Department  
Maguire Center 105 -2944  
2160 S. First Avenue  
Maywood, IL 60153  
 
      
 
 

  
Page 6 of 84 
 Swedis h Cancer Institute  
Desiree Iriarte  
 
 
 
University of Texas Southwestern Medical Center  
Jean Wu, RN, MSN, OCN  
Clinical Research Manager  
Radiation Oncology  
University of Texas Southwestern Medical Center  
5641 Southwestern Medical Ave  
Dallas, TX 75235 -8808  
 
 
 
Princess Margaret Cancer Center  
Sonca Lengoc, B. Sc.  
Clinical Research Data & Regulatory Affairs Coordinator  
Clinica l Research Program (CRP)  
Radiation Medicine Program (RMP)  
Department of Radiation Oncology (DRO)  
Princess Margaret Cancer Centre  
700 University Ave., Toronto, ON M5G 1X6  
2nd Floor, Hydro Building (OPG), North Side, Workstation #78  
    
 
 
 
 
 
 
 
 
 
Stanford Shipping Address:  
For Blood or Tissue Samples:    For Materials and Documents : 
Stephanie Giaretta , CRA for Dr. Daniel Chang    Rachel Freib erg, Ph.D.  
Stanford University Medical Center    Stanford University / Freidenrich Center  
Center for Clinical Sciences Research     
     
     
  
  
 
 
 
 
  
 

  
Page 7 of 84 
  
 
 
  
IRB Versi on 22 -- -- (Submitted  23_May _2019 ) 
 
  
Page 8 of 84 
 TABLE OF CONTENTS   
 
 Page  
PROTOCOL SYNOPSIS  ................................ ................................ ................................ ............  12 
SCHEMA  ................................ ................................ ................................ ................................ ...... 15 
 
1. OBJECTIVES  ................................ ................................ ................................ ........................  16 
1.1 Primary Objectives  ................................ ................................ ................................ ... 16 
1.2 Secondary Objectives  ................................ ................................ ................................  16 
 
2. BACKGROUND  ................................ ................................ ................................ ....................  16 
2.1 Natural History and Management of Pancreatic Cancer  ................................ ...... 16 
2.2 Rational for SBRT for Pancreatic Cancer  ................................ ..............................  17 
2.3 Quality of Life Assessment  ................................ ................................ .......................  18 
2.4 Correlative Studies Background  ................................ ................................ ..............  18 
 
3. PATIENT SELECTION  ................................ ................................ ................................ ....... 20 
3.1 Inclusion Criteria   ................................ ................................ ................................ ..... 20 
3.2 Exclusion Criteria  ................................ ................................ ................................ ..... 21 
 
4. STUDY ENROLLMENT  ................................ ................................ ................................ ...... 22 
5.1  General Guidelines  ................................ ................................ ................................ .... 22 
5.2  Registr ation and Enrollment  ................................ ................................ ....................  22 
 5.3       Informed Consent  ................................ ................................ ................................ ...... 22 
 
5. INDUCTION CHEMOTHERAPY  ................................ ................................ ......................  22 
5.1  mFOLFIRINOX  ................................ ................................ ................................ ........  22 
5.2  Restaging Following mFOLFIRINOX  ................................ ................................ .... 23 
 5.3       Randomization to +/ - SBRT ................................ ................................ ......................  24 
 
 
6. RADIATION TREATMENT PLANNING AND SBRT ADMINISTRATION  ..............  24 
6.1 Pre-SBRT Tests, Procedures, and Planning  ................................ ...........................  24 
6.1.1  Fiducial Placement  ................................ ................................ ........................  25 
6.1.2  Radiotherapy Simulation  ................................ ................................ ..............  25 
6.1.3  Radiation Treatment Planning  ................................ ................................ ..... 26 
6.2 SBRT Treatment Delivery  ................................ ................................ ........................  27 
6.2.1  Use of Radioisotopes / Rad Machines  ................................ ..........................  28 
6.2.2  Prophylactic and Supportive Medicatio ns for SBRT  ................................ . 29 
6.2.3  Other Concomitant Medications  ................................ ................................ .. 30 
 
7. CHEMOTHERAPY AND FOLLOW -UP AFTER RANDOMIZATION  .......................  30 
7.1 Chemotherapy following SBRT  ................................ ................................ ...............  30 
7.2 Follow -up  ................................ ................................ ................................ ...................  30 
7.3 Duration of Study  ................................ ................................ ................................ ...... 31 
7.4 Duration of Follow Up  ................................ ................................ ...............................  31 
7.5 Criteria for Removal from Study  ................................ ................................ .............  31 
7.6 Alternatives  ................................ ................................ ................................ ................  32 
7.7 Compensation  ................................ ................................ ................................ ............  32 
  
Page 9 of 84 
  
8. PHARMACEUTICAL INFORMATION  ................................ ................................ ...........  32 
8.1 Investigational Agent or Device  ................................ ................................ ...............  32 
8.2 Availability  ................................ ................................ ................................ ................  32 
8.3 Agent Ordering  ................................ ................................ ................................ ..........  33 
8.4 Agent Accountability  ................................ ................................ ................................ . 33 
 
9. TOXICITIES AND mFOLFIRINOX DOSING AND MODIFICATIONS  .....................  33 
9.1  Modified F olfirinox (mFFX) Dosing  ................................ ................................ ........  33 
9.1.1  Recommended Modifications for Toxicity  ................................ ..................  34 
9.1.2  Management of Diarrhea during Systemic Treatment Prior to  
 Chemoradiation  ................................ ................................ .............................  38 
9.1.3   SBRT Toxicities and Potential Risks  ................................ ...........................  39   
 
10. DRUG FORMULATION, AVAILABILITY AND PREPARAT ION  ..............................  39 
10.1  Oxaliplatin  ................................ ................................ ................................ ............  40 
10.2  Fluorouracil (5 -FU) ................................ ................................ .............................  42 
10.3  Leucovorin Calcium (Folinic Acid)  ................................ ................................ .... 42 
10.4  Irinotecan (CPT -11, CAMPTOSAR)  ................................ ................................ . 43 
 
11. ADVERSE EVENTS, UNANTICIPATED PROBLEMS, AND DEVIATIONS  .............  44 
11.1  Serious Adverse Events (SAEs)  ................................ ................................ ..........  44 
11.1.1  Reporti ng SAEs  ................................ ................................ .............................  45 
11.2 Unanticipated Problems (UPs)  ................................ ................................ ...........  45 
11.2.1  Reporting  UPs ................................ ................................ ................................  46 
11.3 Adverse Events (AEs) and AE Monitoring  ................................ .......................  47 
11.4 Deviations  ................................ ................................ ................................ .............  48 
11.4.1  Documenting and Reporting Deviations  ................................ .....................  48 
11.5 Study and Subject Reviews  ................................ ................................ .................  49 
 
12. CORRELATIVE/SPECIAL STUDIES  ................................ ................................ ...............  50 
12.1 Laboratory Correlative Studies  ................................ ................................ ...............  50 
12.1.1  Analysis of patient plasma for biomarker development  ............................  50 
 12.2 Collection of Pre - and Post - Treatment Scans, Treatment Planning Scans,  
  and Treatment Plans …………………………………………......…………………51  
12.2.1  Data and Image C ollection  ................................ ................................ ...........  51 
 
13. INVESTIGATOR RESOURCES  ................................ ................................ .........................  51 
 13.1     Qualifications  ................................ ................................ ................................ .............  51 
 13.2     Use of Cancer Center Facilities  ................................ ................................ ................  52 
 13.3     Conflict of Interest  ................................ ................................ ................................ ..... 52 
 
14. STUDY CALENDAR  ................................ ................................ ................................ ............  53 
15. MEASUREMENT OF EFFECT  ................................ ................................ ..........................  54 
15.1 Anti -tumor Effect  ................................ ................................ ................................ ...... 54 
15.1.1  Definitions  ................................ ................................ ................................ ...... 54 
15.1. 2 Disease Parameters  ................................ ................................ ........................  54 
15.1.3  Methods for Evaluation of Measurable Disease  ................................ .........  55 
15.1.4  Duration of Response  ................................ ................................ ....................  55 
  
Page 10 of 84 
 15.1.5  Progression -Free Survival (or other time -to-event parameters)  ...............  55 
15.1.6  Response Review  ................................ ................................ ............................  55 
 
16. MONITORING PLAN AND DATA MANAGEMENT  ................................ .....................  56 
 16.1     Monitoring Plan  ................................ ................................ ................................ .........  56 
 16.2 Study Diagram  ................................ ................................ ................................ ...........  57 
 16.3     Trial Monitoring  ................................ ................................ ................................ ........  58 
16.4 Data Management  ................................ ................................ ................................ ..... 58 
16.4.1  Monitoring and Study Data Review  ................................ ............................  59 
 16.5     Confidentiality  ................................ ................................ ................................ ...........  59 
 
17. STATISTICAL CONSIDERATIONS  ................................ ................................ .................  60 
17.1     Endpoints  ................................ ................................ ................................ ....................  60 
17.1.1  Primary endpoints  ................................ ................................ .........................  60 
17.1.2  Secondary endpoints  ................................ ................................ .....................  60 
 17.2     AnalysisPopulations ……………...….……………………………………………...60  
 17.3 Sample Size ………………………………………………………………...………..60  
17.3.1  Accrual estimates  ................................ ................................ ...........................  60 
17.3.2  Sample size justification  ................................ ................................ ................  60 
17.3.3  Criteria for future studies  ................................ ................................ .............  61 
 17.4 Plan of Analysis ….………………………………………………………………….61  
  17.4.1   Stratification ………………………………………..……………………….62  
 17.5 Stopping Guidelines ……………………………………………………………..….62  
17.5.1  Toxicity monitoring  ................................ ................................ .......................  62 
17.5.2  Interim Analysis for Efficacy of Primary Endpoint:  Progression Free  
 Survival  ................................ ................................ ................................ ...........  64 
 
REFERENCES  ................................ ................................ ................................ ............................  65 
ADDITIONAL REFERENCES  ................................ ................................ ................................ . 66 
 
APPENDICES …………………………………………………………………………………..68  
 Appendix  I – EORTC QLQ -C30 and QLQ -PAN26  ................................ ...........................  69 
 Appendix II – ECOG Performance Status  ................................ ................................ ..........  74 
 Appendix  III – Definition of Menopausal Status  ................................ ................................  75 
Appendix  IV – Eligibility Checklist  ................................ ................................ .....................  76 
Appendix  V – Case Report Forms and Patient Logs  ................................ .........................  79 
 
 
 
  
Page 11 of 84 
 PROTOCOL SYNOPSIS   
TITLE  A Randomized Phase III Study Evaluating 
Modified FOLFIRINOX (mFFX) with or 
without Stereotactic Body Radiotherapy 
(SBRT) in the Treatment of Locally 
Advanced Pancreatic Cancer  
 A PanCRS Group Trial  
PRIMARY OBJECTIVE  To compare the median progression free 
survival for patients treated with mFFX+ SBRT 
with the median progression free survival for 
patient treated with mFFX only . 
SECONDARY OBJECTIVES   To compare  metastasis -free survival for 
pancreatic  patients  following chemotherapy 
+/- SBRT . 
 To compare the one year progression free 
survival for patients treated with mFFX +/ - 
SBRT.   
 To determine the overall survival for patients 
treated with mFFX +/ - SBR T. 
 To determine local progression -free survival 
for patients treated with mFFX +/ - SBRT.  
 To evaluate acute (within 3 months of 
treatment) grade 2 or greater gastritis, fistula, 
enteritis, or ulcer and any other grade 3 -4 
gastrointestinal toxicity within 3 months of 
treatment.  
 To evaluate the utility of FDG -PET for 
treatment planning and estimation of 
progression free survival.  
 To identify new biomarkers in pancreatic 
cancer. 15%  
  
 To evaluate the quality of life before and 
after therapy for patients treated w ith mFFX 
+/- SBRT.  
HYPOTHESES  Systemic chemotherapy followed by 
radiotherapy improves overall survival in 
patients with locally advanced pancreatic 
cancer.  Recent clinical studies have shown that 
FOLFIRINOX chemotherapy is more effective 
than gemcitabine  as first -line treatment in 
patients with metastatic disease.  Similarly, 
aggressive local radiotherapy in combination 
with systemic chemotherapy has also been 
demonstrated to improve overall survival.  We 
hypothesize that optimizing local radiotherapy 
following aggressive systemic chemotherapy 
will further improve overall survival.  
  
Page 12 of 84 
 STUDY DESIGN  Multi -center phase III randomized study 
anticipated to accrue approximately 172 patients 
total at all participating institutions.  
  
Page 13 of 84 
 SUMMARY OF SUBJECT ELIGIBILITY 
CRITERIA  Inclusion:  
 Histologically confirmed adenocarcinoma 
of the pancreas.  
 Determined unresectable by a pancreatic 
cancer surgeon or a multi -disciplinary or 
gastrointestinal oncology Tumor Board  
 Stable or better disease on re -staging scans  
following indu ction mFOLFIRINOX . 
 Typically, pancreatic tumors must be less 
than 8.0 cm in greatest axial dimension at 
the time of treatment planning but final 
determination of eligibility will be based 
upon satisfying the radiation normal tissue 
constraints as specified  below in section 
6.1.3 Radiation Treatment Planning  
 No prior systemic therapy EXCEPT 
patients may be consented and enrolled if 
they have already started mFOLFIRINOX 
for up to four cycles.  
 ECOG 0, 1 , or 2 (see Appendix II) . 
 Acceptable organ and marrow func tion (as 
defined in protocol  section 3.1 ).  
 Ability to understand and the willingness to 
sign an informed consent form.  
 Life expectancy >6 months.  
 
Exclusion : 
 Metastatic disease.
 Children/Age<18 (rarely occurs in this age 
group)
 Prior radiotherapy to the u pper 
abdomen/liver. 
 Patients  who received c hemotherapy  for 
pancreatic cancer other than  up to  4 cycles  
of mFOLFIRINOX  as noted above .
 Uncontrolled illness including, but not 
limited to, ongoing or active infection (or 
infections requiring systemic antibio tic 
treatment), symptomatic congestive heart 
failure, unstable angina pectoris, cardiac 
arrhythmia, or psychiatric illness/social 
situations that would limit compliance with 
study requirements.
 Any concurrent malignanc y other  than non -
melanoma skin cancer,  non-invasive 
bladder cancer, or carcinoma in situ of the 
cervix.  Patients with a previous malignancy 
without evidence of disease for > 5 years 
will be allowed to enter the trial .
 Pregnant and breastfeeding women are 
excluded ; as well as women of child -
bearing potential who are unwilling or 
unable to use an acceptable method of birth 
control (hormonal or barrier method o SEcf 
  
Page 14 of 84 
 PROCEDURES  Optional :  Pancreatic biopsies obtained at the 
time of fiducial placement or in a separate 
procedure, and blood collect ed for biomarker 
analysis  pre-and post -treatment . 
STATISTICAL CONSIDERATIO NS See statistics section.  
 
 
 
 
 
 
SCHEMA  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Page 15 of 84 
  
 
 
 
 
 
 
 
 
1. OBJECTIVES  
 
1.1. Primary Objective   
 
 To compare the median progression -free survival between arm 1 ( mFOLFIRINOX ) 
vs arm 2 ( mFOLFIRINOX +SBRT) . 
 
1.2. Secondary Objectives   
 
 To compare metastasis free survival  for pancreatic patients  following chemotherapy 
+/- SBRT . 
 To compare the one year progression -free survival for patients treated with mFFX  
+/- SBRT.  
 To determine  the overall survival for patients treated with mFFX  +/- SBRT .  
 To determine  local progression -free survival for patients treated with mFFX  +/- 
SBRT.  
 To evaluate acute (within 3 months of treatment) grade 2 or greater  gastritis,  fistula,  
enteritis, or  ulcer and any other grade 3 -4 gastrointestinal toxicit y within 3 mo nths of 
treatment . 
 To evaluate the utility of FDG -PET for treatment planning and estimation of 
progression free survival.  
 To identify new biomarkers in pancreatic cancer.  
 To evaluate the quality of life  before and after therapy for  patients treated with 
mFFX +/- SBRT.  
 
2. BACKGROUND  
 
2.1 Natural History and Management of Pancreatic Cancer   
 
Every year in the United States, there are more than 30,000 newly diagnosed cases of 
pancreatic cancer.  Despite aggressive combined modality treatment approaches, the f ive-
year survival of this disease remains less than 5%(1).  Clearly, more innovative treatments 
are needed to improve overall survival in this group of patients.  
  
Surgical resection is considered to be the only treatment option with curative potential(2).    
However, the majority of pancreatic cancer patients do not have resectable disease at 
presentation.  More than 85% of patients have locally advanced or metastatic disease when 
initially diagnosed.  
 
  
Page 16 of 84 
 Since the late 1990’s, first -line chemotherapy for loc ally advanced/metastatic pancreatic 
cancer has been gemcitabine, a nucleoside analog.  In the pivotal trial for which the FDA 
approved this drug, patients treated with gemcitabine had a modest improvement in survival 
compared to patients treated with 5 -fluorouracil (5FU)(3).  The median survival was 
improved from 4.41 months to 5.56 months.  However, nearly 25% of patients receiving 
gemcitabine were noted to have a clinical benefit compared to 5% of patients receiving 5FU.  
In a recent meta -analysis, the ad dition of platinum analogs to gemcitabine demonstrated a 
survival benefit in patients with a good performance status.  However, additional studies are 
necessary to determine which therapeutics are best combined with gemcitabine(4).  
 
More recently, Conroy e t al reported that a non -gemcitabine containing chemotherapy 
regimen, FOLFIRINOX (5FU, leucovorin, irinotecan, oxaliplatin), provided a significant 
survival benefit compared to gemcitabine ( 30) in patients with metastatic pancreatic cancer.  
Although there  was increased toxicity in those patients treated with FOLFIRINOX, this was 
the first randomized study showing a clinically significant advancement in the treatment of 
patients with advanced pancreatic cancer since gemcitabine was approved by the FDA.  We 
hypothesize that more aggressive systemic chemotherapy followed by intensive local 
radiotherapy will improve overall survival in patients with locally advanced pancreatic 
cancer.  
 
In a single arm multi -center (Stanford  University , Johns Hopkins  University , Memorial 
Sloan Kettering ) phase II study in locally advanced pancreatic cancer, we have previously 
shown that integrating stereotactic body radiotherapy (SBRT, 33 Gy in 5 fractions) with 
systemic gemcitabine chemotherapy resulted in a 1 year freedom from local progression of 
78% and a median overall survival of 13.9 months (Herman et al, Cancer 2014 ).  There was 
minimal toxicity associated with SBRT and the entire radiotherapy course was delivered in 
1 week.  Shortening the duration of radiotherapy from 5 -6 weeks (conventional IMRT) to 1 
week (SBRT) minimizes any delay in the administration of systemic chemotherapy.   
 
Another study in locally advanced pancreatic cancer compared full -dose gemcitabine (1000 
mg/m2) alone to a lower dose of gemcitabine (600 mg /m2) combined with standard 
fractionated radiation (50.4 Gy over 5.5 weeks).  Although the study was closed prior to 
reaching its planned accrual, there was a significant improvement in survival with combined 
gemcitabine and radiation compared to gemcitabi ne alone(5), suggesting that the addition of 
local radiation therapy in pancreatic cancer confers a further survival advantage to systemic 
chemotherapy.  Objective responses were observed in 2.7% in the gemcitabine alone arm 
(95% CI [0.09%, 14.1%]) and 8.8 % in the combined arm (95% CI [1.9%, 23.7%]).  In this 
trial, the dose of gemcitabine was reduced to 600 mg/m2 with radiation and patients required 
a 4-week break prior to resuming full dose gemcitabine.  Grade IV toxicity, principally 
gastrointestinal and  hematologic, was more common in the combined group (41.2 vs. 5.7%; 
p<0.0001).  Although there was an improvement in survival, patients who received 
combined chemoradiation had substantially more toxicity when compared to gemcitabine 
alone.   Because of the  highly conformal and precise nature of SBRT, we hypothesiz e that 
this radiotherapy approach will improve local control and decrease radiation -related toxicity 
in patients with locally advanced pancreatic cancer.  
 
Here, we will conduct a multi -institutiona l randomized trial to compare the effects of 
chemotherapy alone versus chemotherapy and SBRT in patients with locally advanced 
pancreatic cancer.  All patients will receive a modified FOLFIRINOX regimen prior to and 
  
Page 17 of 84 
 following radiotherapy.  The primary end point will be progression -free survival.  
 
 
2.2 Rationale for SBRT for Pancreatic Cancer  
 
Radiation therapy is a widely accepted treatment for pancreatic cancer. The Gastrointestinal 
Tumor Study Group (GITSG) carried out a series of landmark studies demon strating the 
effectiveness of radiation therapy as both adjuvant and definitive treatment in pancreatic 
cancer(6, 7).  Modern radiation treatments have increasingly used conformal fields and dose 
escalation to enhance tumor control(8, 9).   Efforts to incre ase radiation dose to the 
pancreatic tumor without risking normal tissue injury have generally required relatively 
invasive techniques such as interstitial implantation of radioactive metals or intraoperative 
radiotherapy (IORT)(10, 11).   Historically, th e local control rates for conventionally 
fractionated radiotherapy ha ve ranged from 25 -50%.  Local progression of pancreatic 
cancers can result in considerable morbidity, including gastric outlet obstruction and pain 
(12).  
 
The mortality rate for pancreati c cancer approaches 100%.  Current therapies provide only 
partial palliation of symptoms and slight prolongation of survival.  Better treatment is 
clearly needed. SBRT has the potential of significantly improving local progression free 
survival, which coul d translate into both more effective palliation and longer patient 
survival.  Koong et al.  previously used the CyberknifeTM stereotactic radiosurgery system to 
demonstrate that a single dose of 25 Gy stereotactic body radiotherapy was feasible to 
administe r in patients with locally advanced pancreatic cancer(13).  Furthermore, this dose 
of radiation resulted in nearly 100% local progression -free survival and effectively palliated 
symptoms related to the local growth of pancreatic tumors.  Based upon this st udy, these 
investigators also completed a phase II study assessing the efficacy of combining a standard 
five-week course of chemoradiotherapy followed by a stereotactic radiosurgery boost to the 
primary tumor in patients with locally advanced pancreatic ca ncer.  In this cohort of 19 
patients, 100% of tumors were without local progression.  However, all patients eventually 
developed metastases with a median time to progression of 5.5 months  (Koong et al, 
IJROBP 2005).  
 
Another phase II study treated locally advanced pancreatic cancer patients with gem citabine 
followed by 25 Gy of SBRT delivered with Cyberknife and maintenance gemcitabine 
chemotherapy.  In this study, the excellent progression free survival was confirmed from 
previous studies (81%).  The media n overall survival was 11.4 months, median time to 
progression was 9.7 months and 1 year survival was 50%(14).  There were no significant 
acute GI toxicities however, of the 15 patients alive >6 months after SBRT, 7 (47%) 
experienced Grade 2 or greater GI toxicity, with 2 (13%) of the 15 experiencing Grade 3 or 
greater GI toxicity.  
 
More recently, another phase II study of 25 Gy in a single fraction using a linac -based 
approach (TrilogyTM, Varian Medical Systems, Palo Alto , CA) integrated with gemcitabine 
chemotherapy resulted in a 50% overall survival at 1 year and a 94% freedom from local 
progression at 1 y ear.  Four  patients (15%) developed G rade 2 ulcers and 1 patient (5%) 
developed a duodenal perforation (Schellenberg et al , IJROBP 2011).  
 
Recently, we  completed a multi -center phase II trial demonstrating the efficacy of SBRT (33 
  
Page 18 of 84 
 Gy in 5 fractions) in combination with gemcitabine chemotherapy.  No significant toxicities 
were observed and median overall survival was 18 months .  These data compare favorab ly 
to other studies reported in the literature.  Based upon these promising data, we hypothesize 
that adding SBRT to a more aggressive systemic chemotherapy (FOLFIRINOX), will result 
in further improvement in OS in patients with locally advanced pancreatic  cancer.   
 
The proposed randomized study is a logical extension of the previously reported studies and 
will establish the efficacy of adding SBRT to FOLFIRINOX chemotherapy.  Our prior 
multi -center phase II experience demonstrated the feasibility and effi cacy of this approach 
in patients with locally advanced pancreatic cancer.   
 
2.3 Quality of Life Assessment  
 
The major potential benefit of combining SBRT with chemotherapy for locally advanced 
pancreatic tumors is to improve local control and palliation  of symptoms related to local 
progression of these tumors.  In addition, radiosurgical ablation of the primary tumor can 
theoretically prevent distant seeding from the pancreatic tumor itself.  Ultimately, these 
improvements in the treatment of pancreatic cancer may translate into an improved quality 
of life and overall survival.  
 
Quality of life will be assessed using The European Organization for Research and 
Treatment in Cancer quality of life core cancer questionnaire with the pancreatic cancer 
module (EORTC QLQ C -30/ PAN26).  The European Organization for Research and  
Treatment in Cancer Quality of Life Questionnaire (EORTC QOL -C30) is a 
multidimensional , 30-item questionnaire which assesses five functional scales (physical, 
role, cognitive, emotional and social), three symptom scales (fatigue, pain and 
nausea/vomiting), a global health /QOL scale, as well as 6 single items (18).  The EORTC 
QLQ -PAN26 supplements the core questionnaire with 26 items specific for patients with 
pancreatic cancer (19, 20).  These instruments have been validated in patients receiving 
treatment for metastatic and resected pancreatic cancer and are sensitive to identify 
treatment related changes in quality of life.  The quality of life of patients in this study will 
be directly  compared between the 2 randomized arms.  These questionnaires were also used 
in our previous phase II multi -institutional study evaluating SBRT and gemcitabine in 
patients with locally advanced pancreatic cancer.  
 
2.4 Correlative Studies Background  
 
Protein-based biomarkers in blood hold a great promise as diagnostic markers indicative of 
disease states and outcomes in clinical cancer management.  In order to validate large sets of 
candidates markers in bio -banked sample collections, multiplexed and sensi tive detection 
technologies with low sample consumption are required.  Such technologies will not only be 
critical for the discovery of biomarker panels potentially leading to increased predictive 
power in diagnostics but may eventually enable early stage disease detection(21 -22).  
 
Most conventional immunoassays rely on a solid support for capture of the target protein 
and for the removal of excess secondary reporter antibody by washing.  These sandwich 
assays’ susceptibility to nonspecific binding of the secondary reporter to the surface limit 
their sensitivity. Also, any single non -cognate binding event by a detection antibody will 
give rise to a false positive signal.  This is especially challenging when performing 
  
Page 19 of 84 
 multiplexed reactions with many detecti on antibodies thus requiring extensive and careful 
optimization through selection of particular antibody combinations in order to minimize 
non-specific cross reactivity(23 -24).  
 
We have developed a method of protein detection (proximity ligation assay) ut ilizing an 
antibody -based method of detection coupled with a qPCR amplification step (25).  The 
assay  consumes 1 μL of sample with low femto -molar sensitivity, five log linear range, and 
can be multi -plexed without cross -reactivity.  The procedure typicall y relies upon a single 
polyclonal antibody batch for each target protein, simplifying affinity reagent creation for 
novel biomarker candidates.   
 
Based upon our previous studies (26), we will measure plasma levels of the following 
proteins prior to initia ting treatment and 3 months following SBRT as outlined in the 
protocol: VEGF, MIF, CTGF, IL -1alpha, IL -7, galectin -1, TNF -alpha, EpCAM, CEA, 
Adam8, CPA1, ErbB2, IGF -2, CA 19 -9, SLPI, Ch3L, EGFR, Osteopontin, Mesothelin, CA -
125.  We hypothesize that biomark er profile from this group of proteins will be predictive of 
outcome in this group of pancreatic cancer patients with locally advanced disease.  
 
Collection of specimens as outlined above will not be required from all participating 
institutions.  Additional  protein biomarkers may also be assessed.  
 
 
3. PATIENT SELECTION  
 
3.1 Inclusion Criteria  
 
 Histologically confirmed adenocarcinoma of the pancreas.  
 
 Determined unresectable by a pancreatic cancer surgeon or a multi -disciplinary or 
gastrointestinal oncology Tumor Board .  
 
 Stable or better disease on re -staging scans  following induction mFOLFIRINOX. . 
 
 Typically, pancreatic tumors must be less than 8.0 cm in greatest axial dimension at 
the time of treatment planning but final determination of eligibility will b e based 
upon satisfying the radiation normal tissue constraints as specified below in section 
6.1.3 Radiation Treatment Planning . 
 
 No prior systemic therapy EXCEPT patients may be consented and enrolled if they 
have already started mFOLFIRINOX  for up to four cycles.  
 
 ECOG 0, 1, or 2  (see Appendix II).  
 
 Patients must have acceptable organ and marrow function as defined below and 
within 30 days of eligibility confirmation:   
 
- leukocytes  (WBC)  >3,000/µL  
- absolute neutrophil count  (ANC)  >1,500µL  
- platelets  >50,000/µL  
  
Page 20 of 84 
 - total bilirubin  <1.5 X institutional upper limit  of normal  
- AST(SGOT)  / ALT(SGPT)  <2.5 X institutional upper limit of normal  
- Creatinine not above the upper limit of  normal institutional limits .  
 
 Ability to understand and the willingness  to sign a n informed consent form . 
 
 Life expectancy > 6 months .  
 
3.2 Exclusion Criteria  
  
 Children/Age<18 (rarely occurs in this age group)
 
 Metastatic disease .  
 
 Prior radiotherapy to the upper abdomen/liver.  
 
 Patients who have received chemotherapy  for pancreatic cancer,  other than up to 4 
cycles of mFOLFIRINOX  as noted above .   
 
 Uncontrolled illness including, but not limited to, ongoing or active infection (or 
infections requiring systemic antibiotic treatment), symptomatic congestive heart 
failure, un stable angina pectoris, cardiac arrhythmia, or psychiatric illness/social 
situations that would limit compliance with study requirements.  
 
 Any concurrent malignancy other than non -melanoma skin cancer, non -invasive 
bladder cancer, or carcinoma in situ of t he cervix.  Patients with a previous 
malignancy without evidence of disease for > 5 years will be allowed to enter the 
trial. 
 
 Pregnant and breastfeeding women are excluded; as well as women of child -bearing 
potential who are unwilling or unable to use an acceptable method of birth control 
(hormonal or barrier method of birth control; abstinence) to avoid pregnancy for the 
duration of the study.  Male subjects must also agree to use effective contraception 
for the same period as above.  Should a woman becom e pregnant or suspect she is 
pregnant while participating in this study, she should inform her treating physician 
immediately.  
 
 Women who are not post -menopausal (as defined in Appendix I II) and have a 
positive urine or serum pregnancy test or refuse to t ake a pregnancy test.   
 
 
 
4. STUDY ENROLLMENT  
 
4.1  General Guidelines  
 
Subjects will be identified per the recommendation of referring surgeons, Combined 
Modality Tumor Board or equivalent combined modality assessment, or through self -
referral and the advi ce of their attending physician.  No advertisement will be used to recruit 
  
Page 21 of 84 
 subjects.  
 
See Diagram in Section 16.2 for phases and workflow of study.  
 
4.2  Registration and Enrollment  
 
Research staff at each participating center will ensure that all requisi te procedures and tests 
have been performed and complete an Eligibility Checklist (See Appendix IV) to submit to 
Stanford research staff for review.  Stanford research staff will contact the center regarding 
approval of patient’s study participation, and t he patient may then be enrolled and 
registered.   
 
The participating center will register subjects according to their institutional guidelines and 
as per this protocol.   
  
In some patients, an optional additional core biopsy may be obtained for research p urposes 
if consent is provided by the patient.  It may be done at the time of fiducial implantation (in 
patients randomized to SBRT) as described in Section 12.1, Laboratory Correlative Studies; 
or as a separate procedure (for patients randomized to mFFX a lone).  This option will vary 
by participating institution.  
 
4.3       Informed Consent  
 
Consent will be obtained after a clear and thorough discussion between the patient and the 
principal investigator at each participating center.  Consent may be obtain ed either prior to 
starting induction chemotherapy or at any point up through the first 4 treatment cycles. Any 
patients deemed by the principal investigator or co -investigators to be mentally or physically 
incapable of consent will not be included in the study.   
 
Patients may be consented by a PI, Co -Investigator, Research Nurse, or Study Coordinator.  
All research staff will have completed institutional trainings related to research, institutional 
regulatory and HIPAA policies, and managing protected hea lth information (PHI).  
 
5. INDUCTION CHEMOTHERAPY  
 
5.1  mFOLFIRINOX  
 
After study enrollment, patients will receive  (or continue with)  mFOLFIRINOX  (omission 
of bolus 5FU)  as outlined  below, allowing for modifications of dose and schedule as per 
clinical judgme nt of patient’s treating physician.  For patients who have received 
FOLFIRINOX chemotherapy including a 5FU bolus prior to study entry, once consent is 
signed, the 5FU bolus must be omitted.   Because of its improved safety profile without 
sacrificing effic acy, mFOLFIRINOX is commonly administered in the treatment of 
pancreatic cancer ( 31). Modified FOLFIRINOX regimen with improved safety and 
maintained efficacy in pancreatic adenocarcinoma. Pancreas 2013 Nov 42(8):1311 -5.  
 
mFOLFIRINOX  may be administered i n a community practice setting as long as the 
treating oncologist assumes responsibility for all reporting and follow -up requirements.  
  
Page 22 of 84 
 Prophylactic growth factors  may be administered at any time before, during, or after 
chemotherapy cycles.   It is recomme nded that the patient be evaluated at one of the 
participating centers every 3 -6 months.  As standard practices are changing and Leucovorin 
is not widely used, we will allow the omission of this drug during both induction and 
treatment phases of the study.  
 
 
mFOLFIRINOX  to complete a total of 4 cycles, (1 cycle = 14 days)  
 Oxaliplatin 85 mg/m² IV over 2 hours on Day 1, followed by  
 Irinotecan 180 mg/m² IV over 90 minutes on Day 1, followed by  
 Leucovorin* 400 mg/m² IV over 2 hours on Day 1, followed by  
 5FU** 2, 400 mg/m² IV over 46 – 48 hours  
*Leucovorin may be administered concurrently with the last 30 minutes of 
oxaliplatin, and the entire 90 minutes of irinotecan.  
  **5FU is administered via infusion only; there is no bolus injection of 5FU.  
    
  
5.2 Restagi ng Following mFOLFIRINOX   
 
After induction chemotherapy (up to 4 cycles), patients will have a  CT scan for re -staging.   
Re-staging scans should be scheduled within 2 weeks following completion of induction 
mFOLFIRINOX .  To allow for scheduling complication s, outside sites may perform the 
simulation (SIM) scan during the final cycle of chemotherapy up to 4 weeks prior to start of 
treatment.  It the subjects are randomized to the SBRT arm and the SIM was more than 4 
weeks prior to treatment start date, a re -SIM will be performed to ensure that the plan is still 
appropriate for tumor treatment .  
 
 If there is radiological or clinical evidence of disease progression, patient will not 
continue with the randomized portion of this study, but should be treated accord ing 
to treating physician’s discretion .  (Based upon the study by Conroy et al, the 
progression -free survival at 3 months is estimated to be 75%; therefore the number 
of patients evaluated for the protocol and ultimately enrolled will be adjusted 
according ly.)  These patients will continue to be followed as part of the study.  
 If a patient has radiologically responding or stable disease, s/he may proceed with 
randomization as described in the following section .  Patients may undergo surgical 
resection at any  time if clinically appropriate after surgical evaluation.  
 
 
5.3 Randomization to +/ - SBRT  
 
Participating centers will submit re-staging scan reports (and images as requested) within 5 
business days of the scan ’s final  report date to Stanford , along with d ocumentation of 
consent .  These  should be sent in a secure electronic mail message or fax to the PI (Dr. 
Daniel Chang ) and Clinical Research Coordinator  Rachel Freiberg  with subject line:  
“SECURE:  STUDY PATIENT FOR RANDOMIZATION” .  Stanford  research staf f will 
randomize the subject by participating site and within the next business day, will send an 
electronic message to the PI and Research Coordinator f rom the participating center with the 
outcome and instructed treatment plan.  
 
  
Page 23 of 84 
 Randomization will be do ne with R software, a  randomized block design.   It will be 
performed by a Stanford Statistician or the Stanford study coordinator who will maintain a 
password -protected list and assign patients to the treatment arms as each patient is enrolled 
at each inst itution.  Randomization Arm will be confirmed by two coordinators prior to 
electronic notification and written documentation (Note to File) of the treating physician and 
outside research coordinators.  
 
Subject s randomized to SBRT  are allowed up to an 8 -week  break between induction 
chemotherapy  and radiation treatments.  
 
Subjects randomized to mFOLFIRINOX  can continue  directly with that treatment.  Any 
breaks between mFOLFIRINOX  cycles will be determined by the treating Medical  
Oncologist and are permitted f or up to 8 weeks.  
 
If a subject exceeds the allowable 8 -week break between treatments, s/he may continue 
treatment “off protocol” and as recommended by the treating Medical Oncologist or 
according to local standard of care.  These subjects will be followe d for overall survival  and 
progression -free survival .  Subsequent data analysis will be performed on an intention -to-
treat basis.   
 
 
6. RADIATION TREATMENT PLANNING AND SBRT ADMINISTRATION  
 
6.1 Pre-SBRT Tests, Procedures, and Planning  
 
The following will be completed prior to SBRT :  
 
a) Consultation with m edical history and p hysical examination . 
b)   Pathology  with report confirming malignancy . 
c) Labs:  CBC  with differential , CMP (Comprehensive Metabolic Panel) and CA199.  
CEA is optional.  Additionally, up to 20ml of additional blood may be drawn for 
research purposes ( study bloods may also be collected in follow -up visits ).  For 
specific information regarding collection and processing, see Section  12.1 
Laboratory Correlative Studies.    
d) Seed placement:  Gold  fiducial seed placement percutaneously, intraoperatively, or 
under endoscopic ultrasound guidance, which may be performed prior to study 
enrollment.  In some patients, an optional additional core biopsy may be obtained for 
research purposes  if consent is provided by the patient , and may be done  at the time 
of fiducial implantation  (See Section 12.1, Laboratory Correlative Studies ) or in a 
separate procedure . For patients who are planned to be treated with active breathing 
coordinator (ABC) or 4D kV CBCT IG RT, fiducial seed placement is optional.  
e) Scans:  CT or MR . PET/CT scan is recommended  though  not required .   
f) Signed informed consent.  
g) Negative Pregnancy Test  (urine or serum) for female s of childbearing potential  OR 
menopausal  as defined in Append ix III – Definition of Menopausal Status .  
h)  Eligibility confirmation .  
i)  Study registration and randomization . 
j)  Quality of Life Survey:  Baseline collection of EORTC QLQ C -30/ PAN26 QOL . 
  
Page 24 of 84 
  
6.1.1 Fiducial  Placement   
 
Prior to SBRT, 3 to 5 gold fiduci als or ‘seeds’ (99.9% pure, 1 -5 mm length, or 
visicoils)  will be placed directly into the tumor and/or periphery, and when 
possible in the proximal duodenum directly adjacent to the pancreatic tumor.  
The fiducials will be used as surrogates for targeting the tumor position during 
radiation treatment.  The procedure will be done typically under endoscopic 
ultrasound, or if there is a contraindication to endoscopic placement in 
Interventional Radiology under CT guidance; and is expected to be on an 
outpatien t basis.  Fiducials  or clips  may also be implanted prior to enrollment , as 
when  done intraoperatively at the time of attempted surgical resection , which  is 
within the standard of care and may occur regardless of patient eligibility.  
 
6.1.2 Radiotherapy Sim ulation   
 
1) Simulation should be done 5 days or more following placement of fiducials; 
however this may vary per participating institution and is at the discretion of 
each study investigator.   
2) Typically, patients will be positioned supine in an Alpha Cradl e or 
equivalent immobilization device will be custom made for each patient.   
3) Standard free -breathing CT and respiratory -correlated 4 -D pancreatic 
protocol CT will be obtained on each patient.  The 4D -CT scan will be used 
for characterizing target motion d uring quiet respiration. For more accurate 
tumor delineation, an arterial phase pancreatic protocol CT may be obtained 
(typically during expiration breath hold, 1.25 mm slices).  The simulation 
scan should include T4/T5 to L5/S1 (upper abdomen).   
4) IV and o ral contrast must be used for simulation, unless the patient has an 
allergy that cannot be adequately premedicated.  In these situations, the plan 
should be fused with an IV contrast CT scan or MRI (ideally in a similar 
treatment position).   
5) Motion managem ent can be addressed using respiratory gating  or breath -
hold, ( Varian , Elekta, Novalis), respiratory tracking ( Cyberknife ), or 
abdominal compression.  When fiducials are used, f luoroscopy will be used 
to assess motion of implanted gold markers before and a fter compression.  
The goal is to reduce motion from typically 11 -22 mm peak to less than 5 
mm.  If the fiducial motion cannot be decreased to 5 mm or less, then another 
respiratory compensation strategy will be utilized for treatment delivery.  
Prior to s imulation, standard guidelines will be followed.  
6) The selection of which radiotherapy treatment machine to use is left to each 
investigator.  As long as the specified dosimetric parameters for SBRT are 
reached, patients may be treated on any IGRT -enabled m achine.  
7) All patients must start SBRT within 4 weeks of the simulation scan  and 
may have up to an 8 week break between radiation and chemotherapy.  
 
6.1.3 Radiation Treatment Planning  
 
1) When available, an FDG -PET scan is preferred for treatment planning 
purposes and will be acquired on a flat table top whenever possible with the 
  
Page 25 of 84 
 same immobilization devices used for the treatment planning CT simulation.  
2) An SBRT treatment plan will be developed using EclipseTM, Multi -PlanTM or 
PinnacleTM based on tumor geometr y and location at each institution.  
Institutional standards for radiation quality assurance and radiation delivery 
will be utilized.  
3) The final tumor volume (GTV) as identified on the treatment planning CT , 
will be defined by the attending radiation oncol ogist after reviewing the 
diagnostic CT, respiratory -correlated 4D -CT scan, pancreas protocol CT, and 
the FDG -PET/CT scan. These scans will be used to define the ITV (internal 
target volume).  The final PTV (planning treatment volume) expansion will 
consis t of an additional 2 -3 mm of margin expansion, except if the margin 
results in expansion into the duodenum or stomach. In these cases, margin 
expansion is allowed to be non -uniform.  The dose will be prescribed to the 
isodose line that completely surrounds  the PTV.  It is recommended that 
either 6 -12 co -planer fields or 2 -4 conformal arcs be used in the radiation 
treatment plan.  
4) When fiducials are used, c ontours of the fiducials used for target localization 
will be generated on the applicable image sets, to  be used for patient setup on 
treatment.   
5) Radiation dose to the adjacent normal tissue will be minimized and these 
dose constraints should be met:  
-  Duodenum :  Dmax<40 Gy,  V35 < 1cc, V30 < 10cc, V20 < 30cc.  V35,   
V30, and V20 are defined as the volume receiving 35, 30, and 20  Gy, 
respectively. The duodenum (duo@PTV) as defined for these dosing 
parameters includes entire duodenum on the same axial plane as the PTV 
and duodenum 1 cm above and 1 cm below the PTV.  The remainder of 
the normal tissues will b e limited as follows:   
-  Liver  (excluding tumor):  50% should be limited to <12 Gy  
-  Kidney :  Combined volume for both should have 75% <12 Gy  
-  Stomach :  Dmax<40 Gy,  V35 < 1cc, V30 < 10cc, V20 < 30c c. (no more 
than 1 cc of stomach can receive > 35 Gy) 
-  Spinal Cord : no more than 1cc can receive > 15 Gy 
6)  No more than 1cc of the PTV can receive >130% of the prescription dose . 
7)  Greater than 90% of the PTV should receive 100% of the prescription dose . 
8) If above constraints cannot be met, 100% of the GTV must receive at least 33 
Gy and a request for a minor deviation should be submitted.  If this constraint 
still cannot be met, the patient should be withdrawn from the study  and 
treated according to local standard of care .   
 
 
6.2 SBRT Treatment Deliver y 
 
All patients will receive 5 fractions of 8 Gy allowing up to 30% dose heterogeneity, 
delivered over a five -day period (ideally all 5 fractions should be delivered Monday through 
Friday however the 5 fractions may be delivered over 2 weeks as long as the  patient receives 
at least 2 fractions per week ).  SBRT treatment planning and delivery must be completed at 
a participating site.   The recommended interval between induction chemotherapy followed 
by SBRT and between SBRT followed by chemotherapy is 2 -4 we eks.  However, it is 
acceptable to administer SBRT and chemotherapy within 8 weeks of each other.  
  
Page 26 of 84 
  
If a patient is unable to adhere to the protocol  schedule for SBRT treatment,  the patient will 
continue treatment off protocol  and as recommended by the trea ting Medical Oncologist or 
according to local standard of care.  These patients will be followed for overall survival .  
Subsequent data analysis will be performed on an intention -to-treat basis.  
 
All patients must start SBRT within 4 weeks of the simulatio n scan and may have up to an 
8-week break between radiation and chemotherapy.  
 
For LINAC -based , treatment  should entail :  
1)  Initial patient positioning based on either kV or volumetric kV (cone -beam CT) 
imaging with shifts to bony anatomy as appropriate.   
2)  Orthogonal kV/MV or kV/kV projection imaging to verify the location of the 
fiducials prior to delivery of first treatment beam.  A secondary shift based on the 
location of fiducials may be utilized, as indicated by the position of the fiducials.  
For f ree-breathing treatments, kV fluoroscopic images should be obtained to confirm 
the anticipated position of these fiducials during the entire respiratory cycle.  
3)  Active monitoring of treatment delivery accuracy using kV and/or MV projection 
imaging, either  immediately before or during all (or a subset of) treatment fields.  
4)  Patient -specific dosimetric QA performed as per standard practice at each 
participating institution.  
 
For SBRT , treatment should entail : 
1)  Initial orthogonal images obtained to confir m location of fiducial seeds.  
2)  Synchrony respiratory tracking system must be used to correct for respiratory 
associated tumor motion.  This system utilizes a series of optical diodes placed upon 
the patient’s chest wall.  While the orthogonal images are  obtained, the computer 
generates a model correlating the position of the chest wall with the position of the 
internal fiducials.  This model is continuously updated during treatment to correct 
for subtle changes in tumor location.  
3)  QA performed as per standard practice at each participating institution.  
 
For LINAC -based, treatment without fiducial markers should entail:  
1) Patient positioning based on either kV fluoroscopy or volumetric kV (cone -beam 
CT), using vertebral body and stent for initial positio ning.  
2) 4D CBCT (for quiet free breathing) or active breathing coordinator (ABC) breath 
hold stop and go CBCT to be used for IGRT.  Oral water (with a small volume of 
contrast) may be used to help in visualization of the duodenum.  Any biliary stents 
may als o be complimentary in patient positioning.  
3)  QA performed as per standard practice at each participating institution.  
 
 
6.2.1  Use of Radioisotopes / Rad Machines  
 
 Stereotactic radiotherapy will be performed using TrilogyTM or TrueBeamTM 
(Varian, Palo A lto CA) , NovalisTM (BrainLab, Feldkirchen, Germany) , or 
SynergyTM (Elekta AB, Stockholm, Sweden), radiation machines that are 
designed to use multiple beams of radiation to concentrate large doses of 
radiation within a tumor.  The Cyberknife (Accuray, Sunn yvale, CA) is another 
  
Page 27 of 84 
 stereotactic radiotherapy machine that may be used in this study.  Each of these 
machines was specifically designed for image guided radiation therapy (IGRT).  
Because of the innovations in image -guided radiotherapy capabilities assoc iated 
with each of these machines  (or future generation machines) , it is possible to 
deliver highly accurate, stereotactic radiation treatments.  Uncertainties in tumor 
location are minimized because these machines have on -board, volumetric 
imaging for acc uracy in initial patient setup; kV and MV projection imaging 
during treatment is used to monitor delivery accuracy and/or make corrections to 
the patients’ position.   
 
 The radioactive tracer FDG will be used to perform PET scans, a special imaging 
proced ure.  Positron emission tomography (PET) is a type of nuclear medicine 
examination, which is based on the administration of a small amount of a 
radioactive FDG agent.  The tracer (FDG) is a modified form of glucose, a sugar 
normally found in the bloodstrea m and used by cells in the body for energy.  
FDG is eliminated in the urine.  With special imaging equipment, it is possible to 
detect radiation from the administered radioactive agent and obtain images of the 
body.  
 
 RISK INFORMATION  
 
 It is difficult at this time to predict with confidence the percentage rate of 
complications from the proposed SBRT treatment.  However  it is reasonable to 
extrapolate from the current experience with radiotherapy in and around the 
pancreas.  Based upon prior phase I and pha se II studies, we anticipate that the 
toxicities associated with this treatment will be acceptable.  
 
 Toxicity commonly associated with radiation  includes nausea, vomiting, fatigue, 
anorexia and weight loss.  Severe side effects such as gastrointestinal (G I) 
obstruction, perforation, or hemorrhage are uncommon complications, occurring 
in <5% of patients undergoing standard radiation therapy for pancreatic cancer.  
Although we expect a comparable rate of complications with fractionated 
radiotherapy, it is im portant to note that vomiting, GI obstruction, GI 
hemorrhage, anorexia and weight loss are also commonly associated with 
pancreatic cancer progression.  Clinical and radiographic assessments will be 
performed in an effort to identify these effects, ascerta in their etiology and 
provide the most appropriate palliative measures.  Hepatic and renal toxicity is 
not anticipated given the expectation of limited incidental irradiation of these 
organs.  Complications, if any, will be graded according to the CTCAE, N ational 
Cancer Institute, version 4.0  or greater .  We will utilize the RTOG scale as 
necessary for grading acute and chronic radiotherapy toxicities.  
 
 
6.2.2  Prophylactic and Supportive Medications for SBRT  
 
  Patients receiving SBRT should be prescribed a ntiemetics prophylactically and 
for relief of nausea and vomiting symptoms.  W e recommend 1 dose of 
ondansetron (Zofran) or prochlorperazine (Compazine) 30-60 minutes prior to 
each SBRT and if needed another dose after 8 -12 hours, and as needed twice 
  
Page 28 of 84 
 daily  for 5 days following completion of SBRT.  Additional antiemetic measures 
may be used at the discretion of the treating physician.   Administration  of 
Lorazepam is permitted to aid in anxiety and to help with reduction of motion.  
 
  Patients should also be advised to take  a proton pump inhibitor (PPI)  from the 
start of SBRT (Day 1) and continuing for 6 months following completion of 
SBRT .  Over -the-counter PPIs are acceptable and an increase  in medica tion dose 
or duration for symptomatic relief is left to th e discretion of the treating 
physician.  
 
  For symptoms of diarrhea and/or abdominal cramping, patients can take 
loperamide (Imodium)  and/or a dditional antidiarrheal measures at the discretion 
of the treating physician.  In cases of diarrhea, p atients shou ld be instructed to 
increase fluid intake to help maintain fluid and electrolyte balance  and should be 
monitored according to the participating center’s guidelines . 
 
Administration of prophylactic growth factors at any time during the study is 
permissible.   This decision will be at the discretion of the PI or patient's  treating 
physician.  
 
6.2.3  Other Concomitant Medications  
 
 Medications should be monitored by the treating Medical Oncologist.  Therapies 
considered necessary for the patient's well -being may  be given at the discretion 
of the investigator and/or treating physician.  Other concomitant medications 
should be avoided except for analgesics, chronic treatments for concomitant 
medical conditions, or agents required for life -threatening medical proble ms.  In 
general, medications will be prescribed by the attending medical oncologist.  
 
  Patients’ reports of proton -pump inhibitor (PPI) , if applicable, and pain 
medications should be recorded at each visit and entered into REDCap . 
 
 
7. Chemotherapy and Follow -up after Randomization  
 
7.1 Chemotherapy following SBRT   
 
For patients randomized to SBRT, mFOLFIRINOX  should resume within 8 weeks 
following completion of SBRT.  If this schedule cannot be met, the s ubject may continue 
treatment “off protocol” and as recommended by the treating Medical Oncologist or 
according to local standard of care.  These patients will be followed for overall survival and 
progression -free survival.  Subsequent data analysis will b e performed on an intention -to-
treat basis.  
 
Dosing and modification guidelines  for mFOLFIRINOX  are provided in Section 9 , 
however , chemotherapy schedule modifications and dose reductions are allowed and 
are left to the discretion and clinical judgment of the treating medical oncologist .  A 
total of at least 6 cycles of mFOLFIRINOX  is recommended but the total number of cycles 
  
Page 29 of 84 
 is left to the clinical judgement of the treating oncologist.   As standard practices are 
changing and Leucovorin is not widely used,  we will allow the omission of this drug during 
both induction and treatment phases of the study.  
 
Participating centers at all times should follow the Study Calendar (Section 14) and ensure 
that all records and study materials are collected and reported p roperly.  
 
Since mFOLFIRINOX  is an accepted standard of care, chemotherapy may be administered 
in a community setting as long as the treating oncologist assumes responsibility for the 
follow up care and reporting requirements.  It is recommended that the pa tient be evaluated 
at a participating site every 3 -6 months.  
 
 
7.2 Follow -up  
 
All patients will be monitored with clinic visits, labs, and serial imaging (CT or MR scans 
and PET/CT if possible ), and other tests as needed . 
   
Patients deemed resectable at any time during follow -up may proceed to surgery.  These 
patients will be withdrawn from the protocol and followed for survival.  
 
Patients will have consultations  in the first year every three  months following study 
treatment as defined in the Study Calend ar (Section 1 4); a follow up a t 4-6 weeks is optional 
and may be done to assess subject's resectability, or  if clinically indicated by study PIs or 
patient's treating physician .   
 
For years 2 and 3, follow -up is recommended e very 6 months , or until death or study 
withdrawal (due to progression, patient withdrawal, or noncompliance  as defined in Section 
7.5 Criteria for Removal from Study) .  Follow up intervals may be more frequent as 
indicated clinically.  In the event of intolerable toxicity from mFFX, su bjects will still be 
followed per protocol although chemotherapy may be altered or discontinued, the decisions 
of which will be left to the treating Medical Oncologist.   Visits should include:  
 
- Consultation with physica l examination    
- Labs:  CBC, CMP, CA1 99.  CEA  and research bloods are optional . 
- Scans:  CT or MR and PET/CT if possible  (PET/CT is  recommended at 3 month 
follow -up visit but is not required)  
- QOL (Quality of Life) Assessment with EORTC QLQ C -30 / PAN26 survey  
- Adverse Event (AE) evaluation  
- Concomitant Medications:  PPIs and pain medications  as applicable  
- Other tests as appropriate . 
 
Patients who remain on -study will be followed until death and cause of death should be 
obtained when possible.   
 
7.3 Duration of Study  
 
It is anticipated that the total duration of the study will last approximately 72 months  (60 
months for recruitment and a minimum of 12 months of follow -up per individua l).  Patients 
  
Page 30 of 84 
 may be followed for up to  3 years.   
 
7.4  Duration of Follow Up  
 
Patients will remain enrolled on t his protocol until there is evidence that their disease has 
progressed either locally or distantly ; or until study  withdrawal for any reason.  These 
patients will be followed for survival.   
 
Progression may be determined by imaging or clinical criteri a, i.e., increasing ascites and 
cachexia.  We estimate that most patients will remain a subject in this study for 
approximately one year.  Schedule of follow -up will be as according to the Study Calendar  
in Section 1 4. 
 
7.5 Criteria for Removal from Study  
 
Patients will be withdrawn from the study for any of the following reasons:  
  
 disease progression  (as defined in Section 15.1.2 Disease Parameters)  
 patient withdrawal  
 pregnancy  
 patient noncompliance , or failure of the patient to follow instructions of the st udy 
staff 
 protocol director decides that continuing participation could be harmful to the 
patient  
 treatment needed for patient that is not allowed in the study  
 patient is deemed  resectable and proceeds to surgery  
 study cancellation  
 other administrative rea sons 
 unanticipated circumstances.  
 
Patients will continue mFFX on -study until one of these endpoints ; in the event of 
intolerable toxicity fr om mFFX, subjects will still be followed per protocol although 
chemotherapy may be altered or discontinued, the dec isions of which will be left to  the 
treating Medical Oncologist.    
 
Patients withdrawn from the study will be followed for overall survival only.  
 
7.6 Alternatives  
 
Alternative therapies include chemotherapy alone, standard chemotherapy/radiation, or no 
further treatment.  Additionally, patients may choose to receive treatment to improve quality 
of life but which may have no affect on the growth of their cancer.  The risks of 
chemotherapy and standard chemotherapy/radiation include nausea, vomiting, diarrhe a, 
fatigue, bone marrow suppression, and sepsis.  The potential benefits of chemotherapy or 
standard chemotherapy/radiation are prolonged survival.  The risk of pursuing no further 
treatment is tumor progression or spread.  
  
7.7 Compensation  
  
Page 31 of 84 
     
  Subjects  will not be paid to participate in the study.  
 
 
8. PHARMACEUTICAL INFORMATION  
 
8.1   Investigational Agent or Device   
 
 Not applicable.  
 
8.2  Availability  
 
 Not applicable.  
 
8.3        Agent Ordering  
 
Not applicable.  
 
8.4        Agent Accountability  
 
 Not a pplicable.  
 
 
9. TOXICITIES AND mFOLFIRINOX  DOSING AND MODIFICATIONS   
 
9.1  Modified Folfirinox (mFFX)  Dosing  
 
Modified Folfirinox  dosing is  below,  however modifications of dose and schedule are 
allowed as per clinical judgment of patient’s treating medical on cologist .  
Recommendations for toxicity management are in Section 9.1 .1. 
 
mFOLFIRINOX , 1 cycle = 14 days  
 Oxaliplatin 85 mg/m² IV over 2 hours on Day 1, followed by  
 Irinotecan 180 mg/m² IV over 90 minutes on Day 1, followed by  
 Leucovorin* 400 mg/m² IV over 2 hours on Day 1, followed by  
 5FU** 2,400 mg/m² IV over 46 – 48 hours  
 *Leucovorin may be administered concurrently with the last 30 minutes of oxaliplatin, 
and the entire 90 minutes of irinotecan  
 **5FU is administered via infusion only; there is no bolu s injection of 5FU  
    
Subjects should be assessed for Adverse Events (AEs) once during each chemotherapy 
cycle, and A Es should  be recorded  in the  AE Tracking F orm in Appendix V.  Serious 
Adverse Events (SAEs) should be reported promptly as according to th e guidelines in 
this protocol.  (See Section 11 for more information regarding documenting and 
reporting SAEs and AEs.)  
 
Chemotherapy infusion records sho uld be kept i n the patient’s  study chart , either with 
  
Page 32 of 84 
 the Medication Administration Record (MAR) or ot her clinic records which contain :  
Date of infusion , dose completed of each agent , modifications if any and r eason  for 
modificatio n with supporting source documents as needed .  Laboratory results prior to 
infusion  should also be supplied in the patient stu dy chart , as well as the consultation 
note if the patient is seen by the treating physician.    
 
Laboratory results and a dministration dates and doses of each agent should also be 
entered into REDCap . 
 
   9.1.1  Recommended Modifications  for Toxicity  
 
Below are recommendations and not requirements; modifications of 
chemotherapy dose and schedule are allowed as per clinical judgment of 
patient’s treating medical oncologist.  
 
 9.1.1.1 Hematologic Toxicity  
 
NOTE:   mFOLFIRINOX  dose modifications for hemat ologic toxicity are not 
based on CTCAE severity grades . 
 
 For ANC 1,000/mm3–1,200/mm3:  Delay mFOLFIRINOX  until ANC > 
1,200 /mm3 then resume mFOLFIRINOX  at the same dose level.  
 Second or More Occurrence of ANC 1000 /mm3-1200 /mm3:  Delay 
mFOLFIRINOX  until ANC > 1,200 /mm3 then resume mFOLFIRNOX 
with one dose level reduction for all subsequent cycles.  NOTE : The dose 
of leucovorin is not reduced.  
 
 For ANC < 1,000/mm3:  Delay mFOLFIRINOX  until ANC > 1,200 /mm3, 
then resume mFOLFIRINOX  with one dose level reduction for all 
subsequent cycles.   NOTE : The dose of leucovorin is not reduced.  
 
 For Febrile Neutropenia (defined as ANC < 1,000/mm3 and temperature ≥ 
100.5°F): Delay mFOLFIRINOX  until resolution of fever and ANC > 1,200, 
then resume mFOLFIRINOX  with one dose level reduction for all 
subsequent cycles.  NOTE : The dose of leucovorin is not reduced.  
 
 For Platelets 50,000 K/ul – 75,000 K/ ul:  Delay mFOLFIRINOX  until 
platelets > 75,000 then resume mFOLFIRINOX  at the same dose level.  
 Second or More Occurrence of platelets 50,000 K/ul - 75,000 K/ul:  Delay 
mFOLFIRINOX  until platelets > 75,000 K/ul, then resume 
mFOLFIRINOX  with one dose level r eduction for all subsequent cycles.  
NOTE : The dose of leucovorin is not reduced.  
 
 For Platelets < 50,000 K/ul:  Delay mFOLFIRINOX  until recovery to Plts > 
75,000  K/ul then resume mFOLFIRINOX  with one dose level reduction for 
all subsequent cycles.  NOTE : The dose of leucovorin is not reduced.  
 
  9.1.1.2 Non-Hematologic Toxicity  
 
  
Page 33 of 84 
 Diarrhea  
 
 For grade 2 Diarrhea (despite optimal medical management : see Section 
9.1.3): 
 First Occurrence :  Delay mFOLFIRINOX  until recov ery to grade ≤ 1 
or baseline then resume mFOLFIRINOX  at the same dose level.  
 Second or More Occurrence :  Delay mFOLFIRINOX  until recovery to 
grade ≤ 1 or baseline, then resume mFOLFIRINOX  with one dose 
level reduction for all subsequent cycles. NOTE : The d ose of 
leucovorin is not reduced.  
 
 For grade 3 Diarrhea (despite optimal medical management: see Section 
9.1.3):  
 First Occurrence :  Delay mFOLFIRINOX  until recovery to grade ≤ 1 
or baseline, then resume 5 -FU, leu covorin, and oxaliplatin, at the same  
dose level and irinotecan with one dose level reduction for all 
subsequent cycles.  
 Second or More Occurrence :  Delay mFOLFIRINOX  until recovery to 
grade ≤ 1 or baseline, then resume mFOLFIRINOX  with one dose 
level red uction for all subsequent cycles.  NOTE : The dose of 
leucovorin is not reduced.  
 
 For grade 4 Diarrhea (despite optimal medical management):   Delay 
mFOLFIRINOX  until recovery to grade ≤ 1 or baseline then resume 
mFOLFIRINOX  with one dose level reduction for  all subsequent cycles.  
NOTE : The dose of leucovorin is not reduced . 
 
Nausea/Vomiting  
 
The following dose modifications are based on toxicity experienced during a 
cycle.  
 
 For grade 3 Nausea/Vomiting (despite optimal medical management):  
 First Occurrence :  Delay mFOLFIRINOX  until recovery to grade ≤ 1 
or baseline, then resume 5 -FU and leucovorin, at the same dose level 
and oxaliplatin and irinotecan with one dose level reduction for all 
subsequent cycles.  
 Second or More Occurrence :  Delay mFOLFIRINOX  until recovery to 
grade  ≤ 1 or baseline, then resume mFOLFIRINOX  with one dose 
level reduction for all subsequent cycles.   NOTE : The dose of 
leucovorin is not reduced.  
 
 For grade 4 Nausea/Vomiting (despite optimal medical management):  
Delay mFOLFIRINOX  until recovery to grade ≤  1 or baseline, then 
resume mFOLFIRINOX  with one dose level reduction for all subsequent 
cycles.   NOTE : The dose of leucovorin is not reduced.  
 
Mucositis  
 
  
Page 34 of 84 
 The following dose modifications are based on toxicity experienced at any 
time during a cycle.  
 
 For g rade 3 Mucositis:  
 First Occurrence :  Delay mFOLFIRINOX  until recovery to grade ≤ 
1, then resume irinotecan, oxaliplatin, and leucovorin at the same 
dose level and 5 -FU with one dose level reduction for all subsequent 
cycles.  
 For Second or More Occurrence :  Delay mFOLFIRINOX  until 
recovery to grade ≤ 1, then resume mFOLFIRINOX  with one dose 
level reduction in irinotecan and oxaliplatin for all subsequent cycles. 
Dose of 5FU is reduced two dose levels for all subsequent cycles).  
NOTE : The dose of leucovorin  is not reduced.  
 
 For grade 4 Mucositis:  
Delay mFOLFIRINOX  until recovery to grade ≤ 1, then resume 
mFOLFIRINOX  with one dose level reduction for all subsequent cycles.  
NOTE : The dose of leucovorin is not reduced.  
 
Peripheral Sensory Neuropathy  
  
NOTE : Dose modifications for sensory neuropathy are not based on CTCAE 
severity grades.  
 
 For paresthesia/dysethesia interfering with function and persisting 
between treatments:  decrease oxaliplatin by one dose level for all 
subsequent cycles.  
 
 For painful pares thesia/dysesthesia or symptoms that interfere with 
function and ADL, but improve (no longer painful or no longer 
interfering with ADL) between treatments:   decrease oxaliplatin by one 
dose level for all subsequent cycles.  
 
 For painful paresthesia/dysesthes ia or symptoms that interfere with 
function and ADL that persists between treatments :  Discontinue 
oxaliplatin.  
 
 For persistent disabling or life -threatening paresthesia/dysesthesia:   
Discontinue oxaliplatin.  
 
 For pharyngo -laryngeal dysesthesia: increase  the duration of oxaliplatin 
infusion to 6 hours for subsequent cycles.  
 
Oxaliplatin -induced pharyngolaryngeal dysesthesias  
 
Should a patient develop oxaliplatin -induced pharyngolaryngeal dysesthesia, 
her/his oxygen saturation should be evaluated via a pu lse oximeter; if normal, 
an anxiolytic agent may be given and the patient observed in the clinic until 
the episode has resolved. Following resolution of symptoms, patients may 
  
Page 35 of 84 
 continue/resume oxaliplatin if the reaction is NOT determined to be an 
allergic reaction . 
 
A table comparing pharyngo -laryngodysesthesia to platinum hypersensitivity 
reactions is presented below.  
 
Table 1 - Comparison of the Symptoms and Treatment of 
Pharyngolaryngodysesthesias and Platinum Hypersensitivity Reactions  
Clinical Symptom s Pharyngo -Laryngeal 
Dysesthesias  Platinum 
Hypersensitivity  
Dyspnea  Present  Present  
Bronchospasm  Absent  Present  
Laryngospasm  Absent  Present  
Anxiety  Present  Present  
O2 saturation  Normal  Decreased  
Difficulty 
swallowing  Present (loss of 
sensation)  Absen t 
Pruritis  Absent  Present  
Urticaria/rash  Absent  Present  
Cold-induced 
symptoms  Yes No 
Blood pressure  Normal or increased  Normal or decreased  
Treatment  Anxiolytics, observation 
in a controlled clinical 
setting until symptoms 
abate or at the 
physician’s discretion  Oxygen, steroids, 
epinephrine,  broncho -
dilators; fluids and  
vasopressors, if 
appropriate  
 
Venous Thrombembolic Events  
 
 For grade 2 or 3 venous thromboembolic event:   Continue 
mFOLFIRINOX  at the same dose level.  Do not use warfarin for 
therapeu tic anticoagulation.  
 
 For grade 4 venous thromboembolic event:   Discontinue 
mFOLFIRINOX . 
 
Liver Function Tests  
 
 For grade 2 Increased Blood Bilirubin :  Skip irinotecan until bilirubin 
improves to ≤ grade 1 . 
 For hyperbilirubinemia considered at least possibly related to 
irinotecan, then resume irinotecan with one dose level reduction for 
all subsequent cycles.  
 For hyperbilirubinemia considered unrelated to irinotecan, resume 
irinotecan at the previous dose level.  
 
 For grade 3 or 4 Increased Blood Bilirubin:   Delay mFOLFIRINOX  
until bilirubin improves to ≤ grade 1.  If bilirubin is thought to be due to a 
chemotherapy drug, then resume that drug at the next lo wer dose level 
  
Page 36 of 84 
 and the other drugs at the same dose level when total bilirubin improves 
to ≤ grade 1.  
 For hyperbilirubinemia considered at least possibly related to 
treatment (any drug) resume mFOLFIRINOX  with one dose level 
reduction in suspect drug(s) fo r all subsequent cycles.  
 For hyperbilirubinemia considered unrelated to treatment (all drugs), 
resume mFOLFIRINOX  at the previous dose levels.  
 
Allergic Reactions  
 
 For grade 2 allergic reactions :  Interrupt infusion(s).  Manage reaction 
according to instit utional policy.  Restart the infusion(s) when symptoms 
resolve to ≤ grade 1 and pre -treat before all subsequent doses.  
 
 For grade 3 or Grade 4 allergic reactions :  Discontinue infusion.   
Manage reaction according to institutional policy.  Discontinue 
mFOLFIRINOX . 
 
Irinote can dosing and UGT1A1*28 allele homozygosity  
 
Caution should be exercised when dosing irinotecan in patients who express 
homozygous for the UGT1A1*28 allele .  The toxicity is dose -dependent.  
The FDA recommends reducing the dose by one dose level for patie nts 
expressing UGT1A1*28 allele.   For additional information, please refer to 
the package insert.  
 
Other non -hematologic toxicities  
 
 For all other grade 3 non -hematologic toxicities considered at least 
possibly related to mFOLFIRINOX :  Skip the responsible  drug(s) until 
toxicity improves to ≤ grade 1, then resume the responsible drug(s) with 
one dose level reduction for all subsequent cycles.  
 
 For grade 4 non -hematologic toxicities considered at least possibly 
related to mFOLFIRINOX :  Discontinue the respon sible drug(s).  
  
9.1.2 Management of Diarrhea during Systemic Treatment prior to Chemoradiation  
 
 Early Diarrhea (e.g., developing in less than 24 hours after irinotecan 
infusion:  
Lacrimation, rhinorrhea, miosis, diaphoresis, hot flashes, flushing, abdomina l 
cramping, diarrhea, or other symptoms of early cholinergic syndrome may 
occur during or shortly after receiving irinotecan.  Atropine, 0.25 -1. mg IV or 
SC may be used to treat these symptoms. In patients with troublesome or 
recurrent symptoms, prophylact ic administration of atropine shortly before 
irinotecan therapy may be considered.  Additional antidiarrheal measures 
may be used at the discretion of the treating physician.  Combination 
anticholinergic medications containing barbiturates or other agents (e.g., 
Donnatal®) should not be used because these may affect irinotecan 
  
Page 37 of 84 
 metabolism. Anticholinergics should be used with caution in patients with 
potential contraindications (e.g., obstructive uropathy, glaucoma, 
tachycardia, etc.).  
 
 Late Diarrhea (e.g., developing more than 24 hours after irinotecan 
infusion):  
Manage with loperamide, as per standard of care guidelines and package 
insert for irinotecan. Dose modifications are based on toxicity experienced at 
any time during a cycle.  
 
Patients should be op timally managed with anti -diarrheal medications before 
dose modifications are made.  
 
 
 
 9.1.3   SBRT Toxicities and Potential Risks  
 
Prior studies investigating 25 Gy given in a single fraction resulted in a 
combined Grade 3 or higher toxicity in 8% of pa tients.  In our recently 
completed multi -center Phase II study, we did not observe significant toxicities 
related to SBRT with a dose of 33 Gy in 5 fractions.  
 
In another recent study of SBRT for unresectable locally advanced pancreas 
cancer, with a prescr iption dose of 45Gy (7.5 Gy in 6 fractions), no Grade > 3 
toxicities were reported and FFLP was > 91% at 6 months.(29)  
 
Given these recently  reported data of improved FFLP and no increase in toxicity, 
the SBRT prescription dose will be 40 Gy (in 5 fraction s of 8 Gy).   
 
Hepatic and renal toxicity is not anticipated given the expectation of limited 
incidental irradiation of these organs and we have not observed any to date in the 
patients treated with SBRT.  Complications, if any, will be graded according to  
CTCAE v4.0 or higher.  
 
10.  DRUG FORMULATION , AVAILABILITY , AND PREPARATION  
Qualified personnel who are familiar with procedures that minimize undue exposure to 
themselves and to the environment should undertake the preparation, handling, and safe 
disposal o f chemotherapeutic agents in a self -contained, protective environment.  Chemotherapy 
treatment is standard -of-care and can be administered at any qualified medical facility.  
Discard unused portions of injectable chemotherapeutic agents that do not contain a 
bacteriostatic agent or are prepared with unpreserved diluents (i.e., Sterile Water for Injection 
USP or 0.9% Sodium Chloride for Injection USP) within eight hours of vial entry to minimize 
the risk of bacterial contamination.  
The total administered dose  of chemotherapy may be rounded up or down within a range of 5% 
of the actual calculated dose.  
10.1 Oxaliplatin  
  
Page 38 of 84 
 Please refer to the package insert for complete product information.  
Availability  
Oxaliplatin is commercially available a solution in vials con taining 50 mg, 100 mg, and 
200mg at a concentration of 5 mg/mL. The vials do not contain any preservative and 
they are intended for single use.  
Storage and Stability  
Intact vials should be stored at room temperature. According to the manufacturer, 
solution s diluted in D5W are stable for 6 hours at room temperature or 24 hours under 
refrigeration. Solutions diluted in D5W to a concentration of 0.7 mg/mL are reported to 
be stable (sterility not tested) for up to 30 days at room temperature or under 
refrigerat ion.  
Preparation  
The calculated dose of oxaliplatin should be diluted for infusion with 250 mL to 500 mL 
D5W. Oxaliplatin should not be diluted with a chloride -containing solution. Needles, 
syringes, catheters or IV administration sets containing aluminum  should not be used 
with oxaliplatin. As with other platinum compounds, contact with aluminum may result 
in a black precipitate.  
Administration  
Oxaliplatin will be administered by intravenous infusion over 2 hours prior to irinotecan, 
and prior to or conc urrent with leucovorin. Infusion time may be prolonged (up to 6 
hours) in patients experiencing pharyngolaryngeal dysesthesia.  
Toxicity  
The most commonly observed oxaliplatin toxicities include neurotoxicity, GI toxicity, 
and myelosuppression. Three neurot oxicity syndromes have been seen: acute sensory 
neuropathy develops within hours to 2 days after oxaliplatin administration. Symptoms 
include, paresthesias, dysesthesias, and hypothesia of the hands, feet and perioral region. 
Jaw spasm, abnormal tongue sen sation, dysarthria, eye pain and a sensation of chest 
pressure have also been noted. Acute sensory neuropathy symptoms may be exacerbated 
by exposure to cold temperature or cold objects. Symptoms are reversible, usually 
resolving within 14 days and commonl y recurring with further dosing. This syndrome 
has been observed in about 56% of patients receiving oxaliplatin with 5 -FU and 
leucovorin.  
Acute pharyngolaryngeal dysesthesia is reported to occur in 1 -2% of patients. This 
syndrome is characterized by a sub jective sensation of difficulty breathing or 
swallowing without laryngospasm or bronchospasm or objective evidence of hypoxia. 
Avoidance of cold drinks, food and air is suggested in order to minimize 
pharyngolaryngeal dysesthesia. Antianxiety agents (e.g.,  lorazepam) may be used to 
treat pharyngolaryngeal dysesthesias once oxygen saturation has been documented to be 
normal.  
Peripheral neuropathy persisting > 14 days is characterized by paresthesias, 
dysesthesias, and hypothesia. Abnormalities in propriocep tion may also be seen. 
Symptoms of persistent neuropathy may improve upon discontinuation of oxaliplatin.  
Various agents have been used in an attempt to minimize neurotoxicity of oxaliplatin 
(e.g. carbamazepine, Mg+, Ca++). Calcium and magnesium infusions  appear to be 
beneficial in preventing neurotoxicity. Contrary to preliminary findings described in 
  
Page 39 of 84 
 2007, calcium and magnesium do not appear to interfere with tumor response to 
FOLFOX. Calcium and magnesium infusions are generally given before and after 
oxaliplatin, and should not be prepared in the same infusion solution as FOLFOX or 
FOLFIRINOX components.  
Gastrointestinal toxicities include  nausea, vomiting (oxaliplatin is considered to be 
moderately emetogenic) and diarrhea. Grade 3 or 4 neutropenia was  reported in 46% of 
patients receiving FOLFIRINOX, and grade 3 or 4 thrombocytopenia was reported in 
9%.  
Allergic reactions, similar to those seen with other platinum compounds, have also been 
observed in patients treated with oxaliplatin. Reactions range  from rash to anaphylaxis.  
Rarely, oxaliplatin has been associated with pulmonary fibrosis, which may be fatal. 
Oxaliplatin should be discontinued in the presence of unexplained pulmonary symptoms 
(e.g. nonproductive cough, dysphagia) or pulmonary infiltra tes until interstitial lung 
disease or pulmonary fibrosis have been ruled out.  
Recent reports of oxaliplatin extravasation suggest that tissue necrosis may result and 
that oxaliplatin should be considered a vesicant. No standard treatment exists for 
oxali platin extravasation although heat and sodium thiosulfate have both been 
suggested.  
Veno -occlusive disease (VOD) of the liver is a rare complication associated with 
oxaliplatin and 5 -FU. Clinical manifestations of VOD include hepatomegaly, ascites, 
and jau ndice. Histologically, VOD is characterized by diffuse damage in the 
centrilobular zone of the liver. Sequelae of VOD include hepatomegaly, splenomegaly, 
portal hypertension, and esophageal varices. A recent analysis of resected liver 
metastases in 153 pat ients indicated histological  findings consistent with VOD in 6/27 
patients who received 5 -FU alone, 4/17 patients who received 5 -FU and irinotecan, 
20/27 patients who received 5 -FU and oxaliplatin, and 14/16 who received 5 -FU, 
oxaliplatin and irinotecan. T he remaining 66 patients had not received chemotherapy 
prior to resection. There were no such findings in these patients.  
For more information on toxicities associated with oxaliplatin, please see the package 
insert.  
10.2 5-Fluorouracil (5 -FU)  
Please ref er to the package insert for complete product information.  
Availability  
5-FU is commercially available as a 50 mg/mL solution for injection in 10 mL, 20 mL, 
50 mL and 100 mL vials.  
Preparation  
Inspect for precipitate; if found, agitate or gently heat in w ater bath.  
46-48 hour infusion of 5 -FU should be prepared for administration via ambulatory 
infusion pump according to the individual institution’s standards. These solutions may 
be prepared in D5W or 0.9% NaCl. 5 -FU should not be mixed in the same soluti on with 
most parenteral antiemetics.  
Storage and Stability  
Intact vials should be stored at room temperature and protected from light. Slight yellow 
discolor does not usually indicate decomposition. Stability in ambulatory pumps varies 
  
Page 40 of 84 
 according to the pu mp, manufacturer of drug, concentration and diluent. Please refer to 
appropriate reference sources for additional information.  
Administration  
In this study, 5 -FU is administered as an IV infusion over 46 – 48 hours. There is no 
bolus injection of 5 -FU. 
Toxicity  
GI: Nausea, diarrhea, vomiting (mild); stomatitis: 5 -8 days after treatment initiation; 
Myelosuppression: neutropenia (9 -14 days); thrombocytopenia (7 -14 days);  
Dermatologic: Alopecia; nails changes; vein pigmentation; photosensitivity; 
maculopapul ar rash; palmar –plantar erythrodysethesias,  
CNS effects: cerebral ataxia (rare);  
Cardiotoxicity: MI, angina; asymptomatic S –T changes;  
Ocular effects: excessive lacrimation and less commonly, tear duct stenosis.  
Drug Interactions  
Leucovorin enhances the cytotoxicity of 5 -FU by forming a more stable tertiary complex 
with thymidylate synthase. Concommitant adminstration of 5 -FU with warfarin has been 
reported to result in increased INR/prolonged prothrombin time.  
10.3 Leucovorin Calcium (Folinic Acid) ( calcium folinate; citrovorum factor; N 5 -
formyltetrahydrofolate; 5 -formyl -FH4; folinic acid)  
Please refer to the package insert for complete product information.  
Availability  
Leucovorin calcium is commercially available in 50 mg, 100 mg, 200 mg, and 350 mg 
vials for reconstitution, and 50 mL vials of solution at a concentration of 10 mg/mL.  
Storage and Stability  
Intact vials of powder for reconstitution should be stored at room temperature and 
protected from light.  Solutions reconstituted with bacteriostatic w ater for injection are 
stable for up to 7 days at room temperature.  Solutions reconstituted with sterile water 
for injection should be used immediately.  
Intact vials of solution should be stored under refrigeration and protected from light.  
Solutions furt her diluted for infusion are stable for 24 hours at room temperature, and 4 
days under refrigeration.  
Preparation  
Leucovorin may be reconstituted with Bacteriostatic Water for Injection or with Sterile 
Water For Injection.  Solutions should be further dilu ted in D5W, 0.9% NaCl or Ringers 
solution for IV infusion over two hours.  
Administration  
Leucovorin will be administered as a 400 mg/m2 IV infusion over 2 hours after, or 
concurrent with, oxaliplatin and irinotecan. For administration concurrent with 
oxaliplatin (30 minutes) and irinotecan (90 minutes), leucovorin is administered as a 
separate infusion (i.e, not in the same IV solution).  
Toxicity  
The only adverse reactions associated with leucovorin are allergic reactions. These are 
  
Page 41 of 84 
 rare. 
10.4 Irinotecan ( CPT -11, CAMPTOSAR®)  
Please refer to the package insert for complete product information.  
Availability  
Irinotecan is commercially available as a 20 mg/mL solution for injection in 2 mL and 5 
mL vials.  
Storage and Stability  
Intact vials should be stored at controlled room temperature 59° to 86° F (15° to 30°  C) 
and protected from light. Solutions diluted in D5W are reported to be stable for 24 hours 
at room temperature, or 48 hours under refrigeration and protected from light.  
Preparation  
Irinotecan is dilut ed in 5% dextrose (D5W) 500 mL to a final concentration of 0.12 – 2.8 
mg/mL. Stability is improved in D5W as compared with NaCl.  
Administration  
In this study irinotecan will be administered as an IV infusion over 90 minutes, 
following oxaliplatin, and prio r to, or concurrent with, leucovorin.  
Toxicities  
Neutropenia and/or late diarrhea (diarrhea occurring more than 24 hours after irinotecan 
administration) are frequently dose -limiting. Other commonly observed adverse events 
include nausea and vomiting, anor exia (irinotecan is considered moderately 
emetogenic), abdominal cramping, alopecia, asthenia, lymphocytopenia, and anemia. 
Dehydration has occurred as a consequence of diarrhea, particularly when associated 
with severe vomiting. Patients may experience an  acute syndrome of lacrimation, 
diaphoresis, abdominal cramping, and diarrhea (early diarrhea) during or shortly after 
irinotecan administration; this syndrome is thought to be cholinergically mediated and 
may be treated and subsequently prevented with atr opine. Elevations of bilirubin and 
alkaline phosphatase have been reported in up to 84% and 13% of patients, respectively. 
Sporadic cases of pulmonary toxicity, manifested as shortness of breath, nonproductive 
cough, and transient infiltrates on chest X -ray have been reported. Infrequent 
occurrences of mucositis or colitis (sometimes with gastrointestinal bleeding) have been 
observed. Irinotecan is metabolized to Sn -38, an active metabolite. SN -38 is conjugated 
by UGT1A1. Homozygosity for the UGT1A1*28 alle le increases the risk of severe 
neutropenia with irinotecan, and known homozygotes are not eligible for this trial.  
Further information regarding irinotecan may be obtained from the package insert.  
 
 
11. ADVERSE EVENT S, UNANTICIPATED PROBLEMS,  AND DEVIATION S  
 
As Coordinating Center, we will follow guidelines from Stanford’s Research Compliance 
Office and Cancer Clinical Trials Office (CCTO) for defining, identifying, and reporting events 
as defined below.   
 
 
11.1       Serious Adverse Events (SAEs)   
  
Page 42 of 84 
  
A Seri ous Adverse Event (SAE ) is defined as: Any adverse event that meets 
any of the following criteria:  
 Fatal (i.e., the adverse event actually causes or leads to death)  
 Life threatening (i.e., the adverse event, in the view of the investigator, 
places the pati ent at immediate risk of death).  This does not include any 
adverse event that had it occurred in a more severe form or was allowed to 
continue might have caused death  
 Requires or prolongs inpatient hospitalization  
 Results in persistent or significant disa bility/incapacity (i.e., the adverse 
event results in substantial disruption of the patient’s ability to conduct 
normal life functions)  
 Congenital anomaly/birth defect in a neonate/infant born to a mother exposed 
to study drug  
•   Significant medical even t in the investigator's judgment (e.g., may jeopardize 
the patient or may require medical/surgical intervention to prevent one of the 
outcomes listed above).(28)  
 
11.1.1 Reporting SAEs  
 
SAEs should be graded a ccording to the NCI Common Terminology 
Criteria  for Adverse Events, Version 4.0, available at 
http://ctep.cancer.gov/reporting/ctc.html . 
 
SAEs Grade 3 and above require prompt reporting – within 24 hours of 
learning of the event .  Reporting shou ld be done by entering the event 
into OnCore  (Stanford’s clinical trials management system)  and sending 
an email to Stanford Cancer Clinical Trials Office (CCTO) at ccto-
safety@stanford.edu , copying Dr. Daniel Chang  and Stanford  research 
staff (Research Nurse or Research Coordinator s) with subject line:  
“SECURE:  PanCRS STUDY Serious Adverse Event .”  A Case Report 
Form (CRF) describing the event must be supplied and can be sent as an 
attachment to  the email.  It could be generated from the OnCore entry (as 
a pdf or report), or using  the Case Report Form in Appendix V . 
  
Stanford research staff will notify  Stanford IRB via ‘eProtocol’  as per 
regulatory guidelines .  The SAE may also be forwarded to o ther Stanford 
regulatory boards , e.g., DSMC, as applicable .   
 
Any questions, issues, or need for clarification of the event by Stanford 
IRB will go through Stanford study PIs or Coordinators  to the 
participating center research staff .   
 
Participating cen ters are responsible for reporting the SAE to their IRB 
within their institutional timeframes and guidelines.   
 
Participating sites should  also: 
 Place  copies of the SAE Report  in the  patient’s study chart and in the 
regulatory binder  (electronic regulator y binder is allowed) . 
  
Page 43 of 84 
  Follow patient and provide update to Stanford until  any of the below:  
o Resolution of event  
o Resolution of event with sequelae  
o Death of patient  
 
11.2      Unanticipated Problems  (UPs ) 
 
Per Stanford IRB, UPs are events involving risks to  participants or others and 
must meet ALL 3 criteria below : 
 
1.  Unexpected : in terms of nature, severity, or frequency , given (a) the research 
procedures described in the protocol -related documents, and (b) the 
characteristic s of the subje ct population be ing studies; AND  
2.  Related to participation in the research:  or there is a reasonable possibility 
that the incident, experience, or outcome may have been caused by the 
procedures involved in the research; or if a device is involved, probably 
caused by, or associated with the device;  AND  
3.  Harmful :  suggests that the research places subjects or others at a greater risk 
of harm (including physical, psychological, economic, or social harm) than 
was previously known or recognized.  
 
UPs generally will warr ant consideration of substantive changes in the research 
protocol or informed consent process/document, or other corrective actions, in 
order to protect the safety, welfare, or rights of subjects or others. (27)  Due to 
this, UPs will be reported promptly t o Stanford IRB following the below 
guidelines.  
 
A UP may also be an AE or SAE and can be noted as both on CRFs and in 
OnCore.  
 
11.2.1   Reporting UPs   
 
UPs should be entered into OnCore and reported  within 24 hours of 
learning of the event.  Reporting can  be done via email to Stanford 
Cancer Clinical Trials Office (CCTO) at ccto-safety@stanford.edu , 
copying Dr. Daniel Chang  and Stanford research staff (Research Nurse or 
Research Coordinators), with subject li ne:  “SECURE:  PanCRS STUDY 
Unanticipated Problem .”  A Case Report Form (CRF) describing the 
event must be supplied and can be sent as an attachment to the email.  It 
could be generated from the OnCore entry (as a pdf or report), or using 
the Case Report F orm in Appendix V .  
  
Stanford research staff will notify Stanford IRB via ‘eProtocol’ as per 
regulatory guidelines.  The UP may also be forwarded to other Stanford 
regulatory boards, e.g., DSMC, as applicable.   
 
Any questions, issues, or need for clarifi cation of the UP by Stanford IRB 
will go through Stanford study PIs or Coordinators to the participating 
center research staff.   
  
Page 44 of 84 
  
Participating centers are responsible for reporting Unanticipated 
Problems or similar events  to their IRB within their instit utional 
timeframes and guidelines.   
 
Participating sites should also:  
 Place copies of the UP Report  in the patient’s study chart and in the 
regulatory binder (electronic regulatory binder is allowed).  
 Follow patient and provide update to Stanford until an y of the below:  
o Resolution of event  
o Resolution of event with sequelae  
o Death of patient  
 
SAE and UP Reporting Requirements  
Hospitalization  Grade 1  Grade 2  Grade 3  Grade 4/5  
Hospitalization≤  
24 hrs  UP's within 24 
hours  UP's within 24 
hours  Report SAE and UP 
within 24 hours  Report SAE and UP 
within 24 hours  
Hospitalization≥ 
24 hrs  UP's within 24 
hours  UP's within 24 
hours  Report SAE and UP 
within 24 hours  Report SAE and UP 
within 24 hours  
SAE Definition : Fatal, life threatening, requires hospitalization or prolongs hospitalization, results in 
persistent  or significant disablility, causes congenital anomaly/birth defect or significant medical 
event.  
Unexpected Problem (UP) Definition : Unexpected  in terms of nature, severity, or frequency.   
Related  to participation in the research.  And Harmful  suggesting that the research places subjects 
or others at a greater risk of harm.  
To report all UP's and SAEs Grade 3 and above : 1)Enter the event into OnCore,  2)send eamil to  
Dr. Daniel Chang and Stanford research staff (Rachel Freiberg) with the subject line: "SECURE:  
PanCRS STUDY Serious Adverse Event" and 3)Include Case Report Form describing the event and 
submit follow up rep orts for the resolution of the event. For any questions regarding whether an 
event is an SAE or a UP, please email Dr. Chang  and Rachel.  
Dr. Albert Koong:  akoong@stanford.edu                                    
Rachel Freiberg:     rachelf@stanford.edu  
    
 
 
11.3  Adverse Events (AEs) and AE Monitoring  
 
An AE is defined as any untoward medical occurrence in a clinical investigation 
subject, regardless of causal attribution.   
  
Page 45 of 84 
  
All AEs should be graded a ccording to the NCI Common Terminology Criteria 
for A dverse Events, Version 4.0, available at 
http://ctep.cancer.gov/reporting/ctc.html .   
 
AEs should be:  
 Assessed at each consultation or follow -up visit,  
 Assessed during each mFFX cycle (prior to infu sion is acceptable), and  
 Recorded on the AE Tracking form in Appendix V.   
 
Laboratory tests (CBC with differential and CMP) should also be obtained with 
each mFFX administration, and abnormal values also noted on the AE Tracking 
Form indicating AE Grade i f applicable.  
 
AEs should also be:   
- Reported to Stanford as per protocol guideline and upon request  
- Noted in patient study charts and binder  
- Entered into REDCap CRFs  
- Reported to the participating center’s IRB as per their institutional 
guidelines.  
 
AEs in REDCap CRF should remain current and may be requested by Stanford 
for study renewals, audits, reports, analyses or other submissions for Stanford 
IRB, SRC, or DSMC.  AEs may also be reviewed by members of the  study 
monitoring group in meetings, audits, and/or site visits.   
 
Updates and outcomes of AEs, SAEs, UPs, and deviations may take place during 
teleconferences or more frequently as needed.  
 
11.4      Deviations  
 
A protocol deviation is any unapproved discrepancy from a protocol research 
plan or Good Clinical Practice (GCP) guidelines,  except where necessary to 
elimin ate an immediate hazard to trial subjects.                                                             
 
11.4.1 Documenting and Reporting Devia tions  
 
 Serious or Major Deviations  
 
Research staff should promptly report serious or major deviations , or 
those that affect participant eligibility, inform ed consent, or protocol 
endpoints; and /or any deviation that could potentially result in harm to 
participants.  These should be reported within 24 hours of  the deviation  
or of learning of the deviation, by enter ing them  into OnCore.  The 
OnCore record should include the following:   
 description of the deviation,  
 corrective action taken,  
 a statement wheth er the patient was harmed or could have b een 
potentially harmed by the deviation, and  
  
Page 46 of 84 
  whether the deviation was reported to the participating center’s IRB, 
and/or Stanford IRB.  
 
Stanford research staff should also be immediately notified of the 
deviation,  via email to Dr. Daniel Chang , copying  the study R esearch 
Nurse or Research Coordinator  with subject line:  “SECURE:  PanCRS 
STUDY Major Deviation .”  A Case Report Form (CRF) describing the 
event is required and could be generated from the OnCore entry (a s a pdf 
or report)  and attached to the email.  
  
Stanford DSMC reviews deviations in OnCore to ensure completeness of 
the deviation report and ensure the safety of trial participants.  The 
DSMC may request corrective action and/or prompt reporting to Stanfo rd 
IRB.  If reporting to Stanford IRB is required , Stanford’s research staff 
(Study Nurse or Coordinator) will assist with this by entering the 
deviation in ‘eProtocol’.  
 
Any questions, issues, or need for clarification of the event by Stanford 
IRB will g o through Stanford study PIs or Coordinators to the 
participating center research staff.   
 
Participating sites should also:  
 Place copies of the Deviation Report or CRF in the patient’s study 
chart and in the regulatory binder (electronic regulatory binder  is 
allowed).  
 Follow patient and provide update to Stanford until any of the below:  
o Resolution of event  
o Resolution of event with sequelae  
o Death of patient  
 
Participating centers are responsible for reporting deviations to their IRB 
within their institutio nal timeframes and guidelines.   
 
   Minor Deviations  
 
Deviations not meeting the above criteria  for major or ‘serious,’ or that do 
not have a significant effect on the subject’s rights, safety, or welfare, or on 
the integrity of the data -- e.g., conducti ng a protocol -required vi sit out of the 
protocol ‘window ’ -- should be documented on the Deviation L og in 
Appendix V.     
 
Deviations in OnCore or in Deviation logs should remain current at all time, 
and may be requested by Stanford for study renewals, aud its, reports, 
analyses or other submissions for Stanford IRB, SRC, or DSMC.   
 
 11.5 Study and Subject R eviews  
 
Teleconferences will be held every other month for purposes of study and subject 
reviews, issues, and updates.  Participating centers will have at least 1 research 
  
Page 47 of 84 
 team member partake and any pertinent study information will be communicated 
to PIs by the attending research team member(s).  Any issues with patient 
compliance, database entry, toxicities, AE s, UPs , or SAEs, protocol updates or 
review s, or other items will be discussed in calls.   
 
Also, at times of study renewal  and safety or interim analyses, research staff for 
each participating center will compile and submit requested patient data and 
clinical trial efficacy endpoints .  These and o ther pertinent study data  will be 
discussed and reviewed by the monitoring group to confirm whether outcomes 
favor continuation of the study.  
 
Teleconferences will be coordinated by Stanford Research staff and any resultant 
reports will be distributed to p articipating centers’ PI or assigned research team 
member.  
 
12. CORRELATIVE/SPECIAL STUDIES  
 
12.1   Laboratory Correlative Studies  
 
 12.1.1 Analysis of patient plasma for biomarker development  
 
12.1.1.1 Collection of Specimen(s) (optional):  
 
Collaborating centers who partake in this part of the study can have p atients elect 
to participate in this portion of the study on the consent form.   
 
Blood Samples  
 
a)  Blood (EDTA preserved) for research purposes may be drawn after re-staging 
scans when patient is en rolled and registered on-study , and then at each follow -
up along with the patient’s clinical  labs.  For each collection, up to 20ml (2 large 
lavender tubes at 10 ml each) will be drawn.    
 
b)  Immediately after collection, blood will be centrifuged at 3000 RPM for 10 
minutes and plasma collected. The supernatent will be aliquoted for storage at -
80°C into separate tubes.  The pellet will also be stored in a separate tube at -
80°C. 
 
12.1.1.2 Shipping of Specimen(s)  
 
Samples may be shipped to Stanford for an alysis.  Samples will be shipped 
overnight by federal express on dry ice and sent in batches.  
 
12.1.1.3 Site(s) Performing Correlative Studies  
 
All biomarker studies will be performed at Stanford by Dr. Daniel Chang  or in 
the laboratory of a research col laborator.  
 
  
Page 48 of 84 
 We will utilize proximity ligation assay (PLA) to simultaneously interrogate a 
panel of 60 -100 secreted proteins that we have developed for pancreatic cancer 
patients.  PLA is an antibody -based method of detection in which 
complementary single -stranded oligonucleotides are linked to each antibody pair.  
When the 2 antibodies bind in close enough proximity, the local concentration 
increases, allowing for PCR amplification of this signal.  PLA is more sensitive 
than conventional ELISA and can be reliably multi -plexed for the detection of 
multiple protein panels (Fredrikkson et al).  In a pilot study, we have shown that 
when using this method of detection (Chang et al), we can accurately identify 
patients with pancreatic cancer.  In this study, we will expand the number of 
biomarkers and collect plasma at multiple time points during therapy.  The goal 
is to identify a biomarker panel that is predictive of patient outcome and/or 
response to therapy.  We hypothesize that not only is the pattern of sec reted 
biomarkers important but the change in these biomarkers may be even more 
critical for prediction of clinical outcomes.  
 
12.1.1.4 Coding of specimens for privacy protection  
 
At the time of enrollment each patient will be given a specific confidential  
identification number (IDN).  Specimens will be stored under the patient’s IDN.   
The information can be shared with other investigators listed on this protocol.  
Study data will be maintained in password protected computer files (protected 
online database  through Johns Hopkins). Only research personnel will have 
access to this information.  
 
12.2  Collection of Pre - and Post - Treatment Scans, Treatment Planning Scans, and 
Treatment  
              Plans  
 
  12.2.1 Data and Image Collection  
   
   12.2.1.1 All images (CT , PET, or MR ) including  re-staging scans, treatment 
planning scans  and follow -up scans  will be transferred electronically to a secured 
database or on password -protected discs or encrypted drives, using an IDN 
assigned at registration  for each pati ent.  Specific parameters will be 
prospectively collected such as treatment volume and dose to adjacent structures.  
 
   The JHU database is set up to store ROI geometries and dose distributions along 
with the CT.  This design facilitates the investigation of dosimetric effects on 
tumor response and complication utilizing DVH or other attributes of the 3D 
dose.  For Pinnacle, the data can be directly placed in the JHU database via 
scripts.  For other planning systems, DICOM RT data transfer will be used.   
 
 
13. INVESTIGATOR RESOURCES  
 
 13.1 Qualifications  
 
  
Page 49 of 84 
 The study staff will include, but is not limited to, the Principal Investigator, Co -
Investigators, research coordinators, research nurses, and any residents or fellows 
working with the study physicians at each  institution.  Also, laboratory personnel in the 
Principal Investigator’s laboratory will be involved in analyzing the plasma and tumor 
specimens collected from patients.  
 
All study staff will have completed the required training specific for their 
respons ibilities in this study.  Furthermore, each member of the research team from each 
institution will be given a thorough explanation of the protocol and their responsibilities.  
All research investigators will be required to complete proper training through their 
facility and institutional review boards.  
 
 13.2 Use of Cancer Center Facilities   
 
 Patients will be evaluated and treated in their respective institutions.  All radiotherapy 
for this study will be performed in the department of radiation oncology a t the 
participating institution .  Other procedures related to this study (i.e., blood draws, tissue 
biopsy, imaging studies) will be carried out at each institution.  
 
13.3 Conflict of interest  
 
 There is no potential conflict of interest among the research  personnel involved in this 
study.  
  
  
Page 50 of 84 
 14. STUDY CALENDAR  
 
Activity  Induction Chemotherapy  
 R 
 
A 
 
N 
 
D 
 
O 
 
M 
 
I 
 
Z 
 
E 
 
 
  
 
 
 
 
 
 
 
 
 
 Study 
Treatment  Follow -up (Time From Completion 
of Study Treatment)j 
Screen-
ing Study 
Enroll- 
ment  Induction 
Chemo / 
mFFXg  Re- 
  stagingc SBRTd  mFFX  
2 cyclesf 4-8 
wksk 3j 
mos  6j   
mos  9j   
mos  12j   
mos  Yr 2-  
Q 6j  
mos  Yr 3-
Q 6j 
mos  
Biopsy  X             
Negative 
Pregnancy testa X             
Consultation  X X Xg    Xk X X X X X X 
ECOG PS  X X     Xk X X X X X X 
Labs: CB CD, 
CMP, CA19 -9 
(CEA optional)  X Xb Xg  
 Xh  Xk X X X X X X 
Study/research 
labsi (optional)   Xi    Xi Xk X i X i Xi X i X i X i 
Eligibility   X            
Informed 
Consent   X            
Study 
Registration   X            
QOL   X     Xk X X X X X X 
Scan: CT or MR X   Xc   Xk X X X X X X 
PET/CTe Xe       Xe      
AE evaluation     X Xh Xk X X X X X X 
Seed placement      X         
Meds: PPI and 
pain medsj        Xk X X X X X X 
Sim/setup scans      X         
SBRT      Xd         
Maintenance 
mFOLFIRINOX
fh     
  X------- Xfh     
aPregnancy test by urine or serum, for women who are not post-menopausal as defined in Appendix I II.   
b Labs should be done within 30 days of eligibility confirmation .  
cRe-staging scan should be done within 2 weeks following completion of induction mFOLFIRINOX cycles .  
d SBRT should begin within 4 weeks of simulation and 8 weeks of the last chemotherapy; dose is 40 Gy (8Gy in 5 fractions) .  
ePET-CTs are recommended but not required; i f only 1 follow- up PET-CT is possible, recommendation is at 3 months. 
f mFOLFIRINOX should resume within 8 weeks after study treatment, and a ny breaks between chemotherapy cycles should 
not exceed 8 weeks .  Patients may continue on maintenance mFFX as tolerated or per clinical judgment of treating 
physician. 
g Induction chemo/mFFX prior to enrollment is allowed through the 4th  cycle of mFFX.  No more than 4 cycles are 
allowed prior to randomization.  The re-staging scan could be done within 2 weeks of completion of the chemotherapy  
cycle ; records fro m labs and clinic visits are not required; mFFX infusion records should be collected. 
h Labs durin g mFFX  cycles are as per institutional standard or treating Medical Oncologist. AEs should be assessed 
with each cycle of mFFX. 
i Study labs are optional and for research purposes as explained in Section 12. Correlative/Special Studies; and may 
be drawn if patient agrees to this in the consent form. 
  
Page 51 of 84 
 j Follow -up appointments 1 month before or after will be permitted, e.g. for 6 -month follow -up, visit, labs, scan and 
QOL surveys can be done at 5 -7 months.  
k 4-6 week follow -up visit and corresponding activities are optional  and may be added if clinically indicated.  
   
15. MEASUREMENT OF EFFECT  
  
15.1 Anti -Tumor Effect  
 
Patients will be evaluated for anti -tumor effect by follow -up imaging (CT and PET -CT 
imaging) as outlined above.  Initial follow -up scans post -treatment will be compared to 
the patient’s baseline scan , defined as the scan prior and closest to the date of initiating 
chemotherapy . 
 
15.1.1  Definitions  
 
Patients will be eva luable for toxicity and evaluable for objective response at 
follow -up intervals specified in the Calendar above  (Section 1 4). 
 
   15.1.2 Disease Parameters  
 
Pancreatic tumor response will be based upon standard radiographic criteria for 
the treated lesion and will be prospectively recorded in the combined JHU 
secure database. Radiographic response of the pancreatic tumor by diagnostic 
CT scans will be defined according to RECIST criteria as described below:  
  
  CR = complete disappearance of index lesion  
PR = at least 30% decrease in the longest diameter of the index lesion  
PD= more than 20% increase in the longest diameter of the index lesion  
 SD = does not meet criteria for PR or PD  
 
Pancreatic tumor response will also be assessed by FDG -PET scans (when 
available) according to the following criteria:  
CR = target lesion becomes photopenic or standardized uptake value 
(SUV) ratio of tumor/liver less than or equal to 1  
  PR = decrease in SUV ratio of tumor/liver (at least 30%)  
  PD = increase in SUV ratio o f tumor/liver (at least 20%)  
  SD = no significant change in SUV ratio of tumor/liver  
 
Definitions of Progression  
Local tumor progression  will be defined as >=20% increased size on follow -
up CT scan  as compared to baseline CT (scan prior and closest to the  date of 
initiating chemotherapy ).   
 
Distant progression  will be defined as any tumor found outside of the pancreas 
on CT scan.  Local and/or distant progression by both PET and CT scan will be 
recorded separately.  FDG -PET is not required but highly reco mmended as a 
complementary method for determining response.  We will also determine PET 
response with the new PERCIST criteria as reported by Wahl et al. (J Nuc Med 
2009; 50:122S -150S).  
  
Page 52 of 84 
  
 15.1.3 Methods for Evaluation of Measurable Disease  
 
   Pancreas pro tocol CT or chest abdomen pelvis CT  (biphasic imaging, 1.25 mm 
cuts) will be obtained at follow -up intervals as described in Section 14.  Study 
Calendar .  PET-CT scans  should be done at baseline (pre-study) and repeated  if 
possible  at the 3 -month foll ow-up.   
 
   Standard radiographic criteria will be utilized for non -target lesions.  Any 
disease outside of the pancreas will be considered metastatic disease.  If 
possible a biopsy  
 should be obtained to confirm metastasis.  
 
15.1.4 Duration of Response  
 
   The criteria for overall response will be the time from randomization  and first 
sign of local progression or development of metastatic disease.  
 
15.1.5 Progression -Free Survival (or other time -to-event parameters)  
 
 The criteria for time to progression and p rogression -free survival (PFS) will be 
the time from randomization  to documented progression or death.  Individuals 
will be censored at the date of last evaluation for progression if neither event is 
observed.  Overall surviv al will be defined as time from  randomization until 
death  from any cause .  Participants will be censored at the date of last contact if 
the date of death is not observed.  Local PFS will be the duration from 
randomization  to local progression  or death if death occurs before local 
progre ssion .  Metastasis free survival will be the duration from randomization to 
metastasis  or death from any cause , if death occurs before metastasis .  
Individuals will be censored at the time of the last evaluation for local or distant 
progression, respective ly, if neither progression nor death is  observed.     
 
 
 
   
15.1.6 Response Review  
 
 All responses will be reviewed independently by a board certified radiologist at 
the study’s completion.  Each image will be reviewed by the PI from each 
institution period ically and recorded to assess for variability.  Simultaneous 
review of the patient’s chart will also occur at this time.  
 
16. MONITORING PLAN AND DATA MANAGEMENT   
 
16.1 Monitoring Plan   
 
Stanford will serve as the coordinating institution and will conduct stud y audits to 
review each participating centers’ regulatory binders and patient study charts.  These 
  
Page 53 of 84 
 audits will ensure guidelines set forth in this protocol are followed for all aspect s of the 
study including but not limited to regulatory approvals and rene wals; patient eligibility, 
enrollment , treatment , and follow -up; proper documentation and record -keeping ; and 
adverse event and deviation reporting.  Audits will be performed yearly by Stanford 
DSMC ; more frequent monitoring will occur  as needed.  Prelimin ary reviews may also 
take place by Stanford research staff prior to audits.  
 
Each participating center will create and maintain a  paper chart for each subject 
enrolled. Research staff at each center will also enter subject  information into RED Cap 
as per guidelines set forth in this protocol.   
 
Participating center s will supply radiation treatment plan data  upon request by 
uploading scan images and information .  If uploading  is not possible, images and 
reports may be supplied electronically or on enc rypted and/or password -protected discs 
or drives.  Further data may be requested from each institution for study  analys es.   
 
All tools , computers, and systems used for monitoring and analyses will be secure, 
password -protected , and HIPAA compliant.   Share d data will be de -identified and 
unique identifiers will be assigned to ensure patient confidentiality.  
 
See below diagram for phases and workflow of study.  
  
Page 55 of 84 
 16.3   Trial Monitoring   
 
All outcome data (toxicity and efficacy) will be reviewed yearly by the Principal 
Investigator and key Co -Investigators.  This study will also be monitored by the 
Stanford DSMC  as stated above in Section 16.1 .  
 
 Interim reports and/or stu dy renewals will be completed every 10 -12 months from study 
open date, which will be defined as date the study is approved by Stanford IRB.  
Additional and/or m ore frequent reports may be done if determined necessary by the 
study monitoring group (describe d in Section 1 1.2.3).  These reports may include 
information about:  
 Patient accrual and follow -up: overall and at each institution  
 The frequency and severity of adverse events due to protocol therapy  
 Compliance rates of treatment delivery with respect to t he protocol prescription  
 
Adverse event rates will be compared between treatment groups and with the stopping 
guideline thresholds (Section 1 7.5.1).  With the exception of a single, planned interim 
efficacy analysis (Section 1 7.5.2), the interim reports wi ll not contain the results from 
the treatment comparisons with respect the primary outcome (progression free survival) 
or secondary efficacy analyses.  See Section 1 7.5 Stopping Guidelines for additional 
details.  
  
16.4    Data Management  
 
  Study and sub ject information will be entered and maintained in REDCap database . 
Research Coordinators at participating institutions will be given  access to REDCap  and 
enter data directly.  Access will be cre ated once the participating center has obtained all 
regulatory approvals and becomes a participating center in the study.  Once REDCap  
access is established, research staff at each participating center will be provided 
educational materials or traini ng on its use.  
 
  Participating centers can only view and enter data from their institution; Stanford 
research staff will have access to study and subject  data from all participating centers.    
 
Sections or topics required for entry in REDCap  inclu de but are not limited to :  
 Diagnosis and Pathology  
 Demographics  
 Consent  
 Eligibility  
 On-Study Information  
 Off-Study Information  
 Arm Assignment/Randomization  
 Chemotherapy dates, doses, and modif ications  as applicable  
 Deviations  
 SAEs and AEs  
 Consultation information  
 Pertinent medications  
 Results of scans, laboratory and other tests  
  
Page 56 of 84 
  Quality of Life responses  
 
Other information for entry into REDCap  may be requested  or added .   
 
Each center must also begin a patient paper study chart to collect and m aintain subjects’ 
records and study -related documents.  Patient study charts may be reviewed by Stanford 
research team or Stanford DSMC to ensure data validity, integrity, and safety of subjects 
throughout the trial.  
 
Shared data will be de -identified and unique identifiers will be assigned to ensure patient 
confidentiality.  
 
16.4.1   Monitoring and Study Data Review  
 
  When all participating institutions have successfully received IRB approval and 
started enrolling patients, teleconferences will be held e very 2 months  between 
research staff from the Coordinating Center and each participating institution.  A 
study monitoring group consisting of PIs and/or Research Coordinators from 
Stanford University, Johns Hopkins, and Memorial Sloan Kettering will discus s 
and monitor study -related events and issues in these calls.  Included in this 
monitoring Group are:  
 Daniel Chang, Stanford  
 Rachel Freiberg , Stanford  
 Albert Koong, and Joe Herman, MD Anderson  
 
Discussions may include enrollment and accrual  information; da ta updates and 
entry issues;  adverse events, deviations, or patient -related issues; and  other 
study -related matters.  Calls may occur more frequently as needed.  Data review 
and updates will also occur with analysis and completion of Interim Reviews as 
required per protocol.  
 
 16.5 Confidentiality  
 
Study data will be maintained in password protected databases, computer, and/or 
electronic  files.  Only research personnel listed on this protocol will have access to this 
information.  Only the patients unique  IDN will be used.  Specimens will be stored 
under the patient’s IDN.  The patient’s name or other public identifiers will not be 
included in any information shared with other investigators.   
 
 
 
17. STATISTICAL CONSIDERATIONS  
 
17.1 Endpoints  
 
 17.1.1 Primary  Endpoint s 
   
 To compare the median progression free survival between individuals treated 
  
Page 57 of 84 
 with mFOLFIRINOX   +/- SBRT.  
 
17.1.2 Secondary Endpoints  
   
 To compare the one year progression -free survival in pancreatic cancer 
patients following chemotherapy alon e or chemotherapy and SBRT . 
 To compare metastasis free survival in pancreatic cancer patients following 
chemotherapy alone or chemotherapy and SBRT.  
 To compare the overall survival in pancreatic cancer patients treated with 
chemotherapy alone or chemothera py and SBRT.  
 To compare local progression -free survival in pancreatic cancer patients after 
chemotherapy +/ - SBRT.  
 To evaluate acute (within 3 months of treatment) grade 2 or greater gastritis, 
fistula, enteritis, or ulcer and any other grade 3 -4 gastroint estinal toxicity 
within 3 months of treatment.  
 To identify new biomarkers in pancreatic cancer.  
 To evaluate the quality of life of patients before and after either chemotherapy 
alone or chemotherapy and SBRT.  
 
17.2 Analysis Populations  
 
Efficacy analysis will b e conducted on the intent -to-treat population which includes all 
randomized patients and on the per -protocol population .  The per -protocol population 
will include patients who have completed 6 or more cycles of mFolfirinox treatment +/ - 
SBRT.  
 
17.3 Sample Size  
 
17.3.1 Accrual estimates  
 
The study accrual  goal is 172 randomized subjects  over 60 months among all 
participating institutions  (i.e. 2 -3 patients per month) .  Due to varying eligible 
patient populations, enrollment may differ at participating centers.   
 
Stanford  accrual goal is 6-12 randomized patients annually.  
 
17.3.2 Sample Size Justification  
 
Progression free survival is defined as the time from randomization until 
progression or death.  Individuals who are lost to follow -up prior to death or 
progre ssion will be censored at the date of last progression evaluation.  Based 
upon previous research, the median progression free survival for individuals 
treated with mFolfirinox alone is estimated to be 6 months.  A sample size of 172 
randomized participants  (86 per arm) has 9 1% power to detect an increase to 
10.2 months for individuals treated with mFolfirinox plus SBRT as compared to 
6 months for those receiving mFolfirinox alone assuming  that the data follows an 
exponential distribution as well as a  60 months of accrual and a minimum of 12 
months of follow -up after randomization in a 2-sided  test with a  type 1 error rate 
of 0.05.   
  
Page 58 of 84 
  
 
17.3.3 Criteria for Future Studies  
 
We anticipate that fractionated SBRT with IGRT based linac systems will result 
in similar  progression free survival at one year (80 -90%) to single fraction SBRT 
but with a (20%) decrease in late gastrointestinal toxicity at one year.  The 
current patient population will serve as a comparator for the future trials in terms 
of time to progressio n and provide additional information with regards to 
radiation treatment planning.  
 
17.4 Plan of Analysis  
  
Demographic and clinical characteristics of patients and the characteristics of treated 
lesions (volume, location, and modality) will be summarized by means, medians, 
standard deviations, ranges and proportions as applicable.  
 
Time to event outcomes (overall survival, metastasis free survival, and progression free 
survival) will be summarized using Kaplan -Meier curves and medians with 95% 
confidence intervals calculated using Greenwood’s formula.  Cox proportional hazards 
models will be used to compare treatment groups and to assess risk factors (e.g. biologic 
markers and PET volume ).  The effect of site will be tested in the Cox  models ; the effect 
of whether or not the patients received Leucovorin will also be tested in the Cox models .  
The level of response  (and other categorical outcomes) will be tabulated at each follow -
up interval.  Logistic regression and Cox models will be used to assess the pro portion 
with a response category depending upon the level of censoring prior to the annual visit.   
 
The measurements of the volume of the pancreatic tumors based upon CT and PET -CT 
scans will be compared using paired t -tests or Wilcoxon signed -rank tests as appropriate.  
The agreement between pancreatic tumor measurements will be compared among the 
three institutions using correlation coefficients, percentage agreement, and inter -
correlation coefficients .   
 
Quality of life outcomes will be assessed at eac h time interval and compared using the 
recommended guidelines from the module.  Differences in QOL for the two treatment 
groups will be explored using a repeated measures model in order to account for the 
within -patient correlation.  Special interest will be placed on exploring the aspects of 
QOL which are known to be impacted by SBRT.  
 
 At this time all research on biomarkers for disease progression is exploratory.  The 
goal is to potentially identify biomarkers that are associated with disease progression .  
Should any biomarkers be identified, their impact on the time to event outcomes will be 
summarized using Kaplan Meier curves and they will be tested using Cox proportional 
hazards models.  
 
Quality of life at each interval will be calculated and compared  using the recommended 
guidelines from the module (available by E -mail: c.d.johnson@soton.ac.uk ).  Efficacy 
outcomes with repeated measurements over time (e.g. quality of life) will be analyzed 
using a general ized estimating equation (GEE) approach to account for within -patient 
  
Page 59 of 84 
 correlation.  
 
Adverse events will be tabulated by type and grade at each follow -up.  All adverse 
events will be reported to the Data Safety and M onitoring Board (DSMB), GI Clinical 
Resea rch Groups  (CRG) if applicable , and each institution’s IRB , as well as to Stanford 
as the Coordinating Center according to the guidelines set forth in this protocol .  The 
expected toxicity rate is 12% or less and a continuous Bayesian stopping guideline ha s 
been developed (see section 17.5.1, p 64) representing the 12% toxicity rate. The study 
may be stopped before reaching the accrual goal at the recommendation of any of these 
groups  based upon stopping guidelines for toxicity as described below . 
 
17.4.1  Stratification  
 
  We will stratify by ECOG performance status (0 and 1 vs 2).  
 
 17.5 Stopping Guidelines  
 
17.5.1 Toxicity Monitoring  
 
Adverse events or toxicities will be monitored throughout the study and follow -
up periods with Grade 4 and higher events re ported to Stanford promptly, as 
outlined in Section 1 1. Toxicities, Adverse Events, and Reporting Requirements.  
Grade 3 and lower adverse events will be recorded on AE logs at each institution 
and reported to Stanford as requested (See Section 1 1.2.3).  An interim review of 
toxicities between the two arms will be conducted by all co -investigators  when 
16 evaluable patients  have been enrolled . If there is a >20% increase in G3 or 
higher toxicities in the treatment arm compared with to the control arm, then we 
will revis e the protocol as appropriate.  
 
In our recently completed Phase II study using 33Gy in 5 fractions , there were no 
Grade 5 toxicities and the G rade 3-4 toxicity rate attributable to SBRT was 8% .  
For this study, we would expect the observed rat e of grade 3 or higher toxicities 
with the first 6 month s to be slightly higher due to the toxicity related to 
Folfir inox and to the expansion to additional sites; however, we expect the 
overall rate to be less than 12% .  A toxicity level of 20% would be c onsidered 
the upper boundary.  
 
We have developed a continuous Bayesian stopping guideline with a prior 
distribution of Beta ( 6, 44), rep resenting a toxicity rate of 15% (just above our 
expected rate).  The guidelines will recommend that the therapy be re -evaluated 
if the posterior probability that the toxicity rate exceeds the 20% boundary is 
greater than 65%.  Once an initial cohort of 10 participants has been enrolled and 
followed for 6 months, toxicity will be monitored continuously.  Table 1 below 
summa rizes the stopping guideline boundaries for SBRT related events.  
 
 
 
 
    Table 1  
  
Page 60 of 84 
 Cohort size  Observed number of toxicities 
that trigger re -evaluation  
11-14 5 
15-20 6 
21-27 7 
28-33 8 
34-39 9 
40-46 10 
47-52 11 
53-58 12 
59-65 13 
66-71 14 
72-78 15 
79-84 16 
85-86 17 
 
 
The probability of triggering the stopping guidelines was assessed for a range of 
underlying toxicity rates based upon simulations with 5000 replicates (Table 2).  
In the expected range of toxicity, the probability of stopping to re -evaluate was 
less than  5% if the underlying toxicity was 10% ; whereas the probability of 
stopping to re -evaluate for unacceptable levels was 74.2% or higher.  
 
    Table 2  
True underlying  
toxicity rate  Probability of triggering  
stopping guideline boundaries  
1% 0% 
5% 0.1% 
8% 1.4% 
10% 4.2% 
12% 11.3% 
15% 31.2% 
20% 74.2% 
25% 95.7%  
 
  
17.5.2 Interim Analysis for Efficacy of Primary Endpoint:  Progression Free 
Survival  
 
A single interim efficacy analysis will be performed at 36 months, the calendar 
mid-point for the trial.  Given the expected median time to progression given in 
Section 1 7.3.2, we expect to observe the progression endpoint (progression or 
death due to any cause) for 160 participants (83 in the folfirinox alone arm and 
77 in the SBRT + folfi rinox arm).  After 36 months, we anticipate observing 71 
progressions, which translates to 44% of the total information.  Monitoring will 
be performed via an O’Brien -Fleming alpha spending function with an interim 
assessment at 44% of information time.  Th e calculations are made assuming 
two-sided symmetric boundaries with a total of 2 analyses (1 interim and one 
final) and a total alpha 0.05 .  The trial will be stop ped early for efficacy if the 
  
Page 61 of 84 
 99.695 % confidence interval of the hazard ratio does not conta in 1, i.e. a two -
sided alpha spending of 0.00305 on the first interim analysis (0.001525 in each 
direction) . 
 
 
  
Page 62 of 84 
  
References  
 
1.  Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin  2007;57:43 -66. 
2.  Cameron JL, Riall TS, Coleman J,  et al. One thousand consecutive pancreaticoduodenectomies. Ann 
Surg 2006;244:10 -5. 
3.  Burris HA,3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with 
gemcitabine as first -line therapy for patients with advanced pancreas can cer: A randomized trial. J Clin Oncol 
1997;15:2403 -13. 
4.  Heinemann V, Boeck S, Hinke A, et al. Meta -analysis of randomized trials: Evaluation of benefit from 
gemcitabine -based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008;8:82.  
5.  Loehrer PJ, Powell ME, Cardenes HR, et al.  A randomized phase III study of gemcitabine in 
combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic 
cancer: E4201. Journal of clinical oncolo gy 2008;26:abst. 4506.  
6.  Kalser MH, Ellenberg SS. Pancreatic cancer. adjuvant combined radiation and chemotherapy following 
curative resection. Arch Surg 1985;120:899 -903. 
7.  Further evidence of effective adjuvant combined radiation and chemotherapy fol lowing curative 
resection of pancreatic cancer. gastrointestinal tumor study group. Cancer 1987;59:2006 -10. 
8.  McGinn CJ, Zalupski MM. Combined -modality therapy in pancreatic cancer: Current status and future 
directions. Cancer J 2001;7:338 -48. 
9.  Ben-Josef E, Shields AF, Vaishampayan U, et al. Intensity -modulated radiotherapy (IMRT) and 
concurrent capecitabine for pancreatic cancer. Int J Radiat Oncol Biol Phys 2004;59:454 -9. 
10.  Willett CG, Del Castillo CF, Shih HA, et al. Long -term results of intraope rative electron beam 
irradiation (IOERT) for patients with unresectable pancreatic cancer. Ann Surg 2005;241:295 -9. 
11.  Crane CH, Beddar AS, Evans DB. The role of intraoperative radiotherapy in pancreatic cancer. Surg 
Oncol Clin N Am 2003;12:965 -77. 
12.  Willett CG, Czito BG, Bendell JC, et al. Locally advanced pancreatic cancer. J Clin Oncol 
2005;23:4538 -44. 
13.  Koong AC, Le QT, Ho A, et al. Phase I study of stereotactic radiosurgery in patients with locally 
advanced pancreatic cancer. Int J Radiat Oncol  Biol Phys 2004;58:1017 -21. 
14.  Schellenberg D, Goodman KA, Lee F, et al. Gemcitabine chemotherapy and single -fraction stereotactic 
body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2008.  
15.  Chang DT, Schellenberg D,  Shen J, et al. Stereotactic radiotherapy for unresectable adenocarcinoma of 
the pancreas. Cancer 2009;115:665 -72. 
16.  Chang BK, Timmerman RD. Stereotactic body radiation therapy: A comprehensive review. Am J Clin 
Oncol 2007;30:637 -44. 
17.  Timmerman R, B astasch M, Saha D, et al. Optimizing dose and fractionation for stereotactic body 
radiation therapy. normal tissue and tumor control effects with large dose per fraction. Front Radiat Ther Oncol 
2007;40:352 -65. 
18.  Groenvold M, Klee MC, Sprangers MA, et a l. Validation of the EORTC QLQ -C30 quality of life 
questionnaire through combined qualitative and quantitative assessment of patient -observer agreement. J Clin 
Epidemiol 1997;50:441 -50. 
19.  Fitzsimmons D, Kahl S, Butturini G, et al. Symptoms and quality o f life in chronic pancreatitis assessed 
by structured interview and the EORTC QLQ -C30 and QLQ -PAN26. Am J Gastroenterol 2005;100:918 -26. 
20.  Fitzsimmons D, Johnson CD. Quality of life after treatment of pancreatic cancer. Langenbecks Arch 
Surg 1998;383:14 5-51. 
21.  Etzioni R, Urban N, Ramsey S, et al. The case for early detection. Nat Rev Cancer 2003;3:243 -52. 
22.  Aebersold R, Anderson L, Caprioli R, et al. Perspective: A program to improve protein biomarker 
discovery for cancer. J Proteome Res 2005;4:110 4-9. 
23.  de Jager W, Rijkers GT. Solid -phase and bead -based cytokine immunoassay: A comparison. Methods 
2006;38:294 -303. 
24.  Elshal MF, McCoy JP. Multiplex bead array assays: Performance evaluation and comparison of 
sensitivity to ELISA. Methods 2006;38: 317-23. 
  
Page 63 of 84 
  
25.  Fredriksson S, Dixon W, Ji H, et al. Multiplexed protein detection by proximity ligation for cancer 
biomarker validation. Nat Methods 2007;4:327 -9. 
26.  Fredriksson S, Horecka J, Brustugun OT, et al. Multiplexed proximity ligation assays to p rofile putative 
plasma biomarkers relevant to pancreatic and ovarian cancer. Clin Chem 2008;54:582 -9. 
27.  Events and Information that Require Prompt Rep orting to the IRB, Stanford University HRPP Policy 
Guidance, Research Compliance Office, GUI -P13, rev 9 /2012.  
28.  Stanford Cancer Institute:  Serious Adverse Event Reporting, Standard Operating Procedure, Version 5, 
May 30, 3012 . 
29.  Tozzi A, Comito T, Alongi F, et al.  SBRT in unresectable advanced pancreatic cancer:  preliminary 
results of a mono -instit utional experience. Radiation Oncology  2013;8:148.  
30.   Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic 
cancer. N England Journal of Medicine 2011; 2:364(19):1817 -25. 
31.   Mahaseth H , Brutcher E, et al . Modif ied FOLFIRINOX regimen with improved safety and 
maintained efficacy in pancreatic adenocarcinoma.  Pancreas 2013 Nov 42 (8): 1311 -5.)  
 
 
 
Additional References  
Chang S, Zahn JM, Horecka J, et al. Identification of a biomarker panel using a multiplex proxim ity ligation 
assay improves accuracy of pancreatic cancer diagnosis. J Translational Med  2009;7:105.  
Herman JM , Chang DT , Goodman KA , Dholakia AS , Raman SP , Hacker -Prietz A , Iacobuzio -Donahue 
CA, Griffith ME , Pawlik TM , Pai JS , O'Reilly E , Fisher GA , Wild AT , Rosati LM , Zheng L , Wolfgang 
CL, Laheru DA , Columbo LA , Sugar EA , Koong AC . Phase 2 Multi -Institutional Trial Evaluating 
Gemcitabine and Stereotactic Body Radiotherapy for Patients with Locally Advanced Unresectable 
Pancreatic Adenocarcinoma. Cancer. 2015 April 1: 121(7):1128 -37. 
Huguet F, Andre T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in 
locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 
2007 ;25:326 -31. 
Krishnan S, Rana V, Janja n NA, et al. Induction chemotherapy selects patients with locally advanced, 
unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 
2007 ;110:47 -55. 
Ko AH, Quivey JM, Venook AP, et al. A Phase II Study of Fixed -Dose Rate Gemcitabine Plus Low -Dose 
Cisplatin Followed by Consolidative Chemoradiation for Locally Advanced Pancreatic Cancer. Int J 
Radiat Oncol Biol Phys 2007 ;68:809 -16. 
Koong A, Christofferson E, Le QT, et al. Phase II Study to Assess the Efficacy of Con ventionally Fractionated 
Radiotherapy Followed by a Stereotactic Radiosurgery Boost in Patients with Locally Advanced 
Pancreatic Cancer. Int J Radiation Oncology Biol Phys 2005 ;63:320 -32. 
Simon, R (1989) Optimal two -stage designs for phase II clinical tria ls.  Controlled Clinical Trials; 10: 1 -10. 
Efird, J Blocked Randomization with Randomly Selected Block Sizes.  Int J Environ Res Public 
Health2011: 8(1): 15 -20. 
 
Block randomization: blockrand package information can be found at   https://CRAN.R -
project.org/package=blockrand  
  
Page 64 of 84 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Page 65 of 84 
 A P  E N D I C E S   
 
  
Page 66 of 84 
  
 
 
 
 
 
 
 
 
 
Appendix I  
 
 
 
 
 
EORTC QLQ -C30 and  
 
EORTC QLQ -PAN26  
 
 
 
 
 
 
  
Page 67 of 84 
 
 
  
Page 68 of 84 
 
 
  
Page 69 of 84 
 
 
  
Page 70 of 84 
 
 
 
Page 71 of 84  
Appendix II  
 
 
ECOG  Performance  Status * 
 
Grade  Description  
0 Fully active, able to carry on all pre -disease 
performance without restriction  
1 Restricted in physically strenuous activity but 
ambulatory and able to carry out work of a light or 
sedentary nature, e.g., light house work, o ffice 
work  
2 Ambulatory and capable of all selfcare but unable 
to carry out any work activities. Up and about 
more than 50% of waking hours  
3 Capable of only limited selfcare, confined to bed 
or chair more than 50% of waking hours  
4 Completely disabled.  Cannot carry on any 
selfcare. Totally confined to bed or chair  
5 Dead  
* As published in Am. J. Clin. Oncol.:  
Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., 
Carbone, P.P.: Toxicity And Response Criteria Of The Eastern Co operative Oncology 
Group. Am J Clin Oncol 5:649 -655, 1982.  
 
  
Page 72 of 84 
  
 
Appendix I II 
 
 
Definition of Menopausal Status:  
 
 
Menopausal will be defined according to the following criteria:  
 
Post-menopausal:  
 
•  Woman 60 years of age or older  
•  Woman aged 45 -59 years  with spontaneous cessation of menses for at least 12 months prior 
to registration  
•  Woman aged 45 -59 years with cessation of menses for less than 12 months prior to 
registration AND an FSH level in the postmenopausal range (or >34.4 IU/L if institutional  
range is not available)  
•  Woman aged 45 -59 years on hormone replacement therapy who have discontinued hormone 
replacement therapy at diagnosis of breast carcinoma and have an FSH level in the 
postmenopausal range according to institutional/laboratory sta ndards (or 34.4 IU/L if the 
institutional range is not available)  
•  Prior bilateral oophorectomy  
•  Woman younger than 60 years of age who have had a prior hysterectomy (without bilateral 
oophorectomy) AND who have an FSH level in the postmenopausal range  (or >34.4 IU/L if 
institutional range is not available)  
Pre- or peri -menopausal:  Not meeting definition for postmenopausal outlined above  
 
 
 
 
 
 
 
  
Page 73 of 84 
  
Appendix IV 
 
Eligibility Checklist  
 
Protocol Information  
Title  Pancreatic Cancer Radiotherapy Study Group (P anCRS) Trial:   A 
Randomized Phase III Study Evaluating Modified FOLFIRINOX 
(mFFX) with or without Stereotactic Body Radiotherapy (SBRT) in 
the Treatment of Locally Advanced Pancreatic Cancer  
Number  27492  
Principal Investigator  Daniel Chang  
 
Subject Inf ormation  
Subject Name: ______________________________________________  
Study ID: ____________________________________  
Gender:     Male      Female  
 
Inclusion/Exclusion Criteria  
Inclusion Criteria  (From IRB approved pro tocol)  Yes No Supporting Documentation*  
1. Histologically confirmed adenocarcinoma of the 
pancreas          
2. Induction mFOLFIRINOX  up to 4 cycles          
3. Stable or better disease on re -staging 
scans          
4. Deter
mined unresectable by a pancreatic cancer s urgeon or a 
multi -disciplinary or gastrointestinal oncology Tumor 
Board          
5. Typically, pancreatic tumors must be < 8.0 cm in 
greatest axial dimension at time of treatment planning 
but final determinati on of eligibility will be based upon 
satisfying the radiation normal tissue constraints as 
specified in protocol (Section 6.1.3 - Radiation 
Treatment Planning).          
6. ECOG 0, 1, or 2     
  
Page 74 of 84 
 7. Acceptable organ and 
marrow function as defined below and within 30 days 
of eligibility confirmation:  
a. Leukocytes  >3,000/µL  
b. ANC   >1,500µL  
c. Platelets  >50,000/µL  
d. Total bilirubin  <1.5 X institutional   
 upper  limits of normal  
e. AST (SGOT)/ALT (SGPT)  <2.5 X institutional  
                                                  upper limit of normal  
f. Creatinine not above the upper limit of  normal 
institutional limits           
8. Ability to understand and the willingness to sign a 
written informed consent document          
9. Life expectancy >6 months     
 
Exclusion  Criteria  (From IRB approv ed protocol)  Yes No Supporting Documentation*  
1. Children / Age <18 years          
2. Metastatic disease          
3. Prior radiotherapy to the upper abdomen/live r         
4. Prior chemotherapy for pancreatic cancer, other than up 
to 4 cycles of mFOLFIRINOX          
5. Uncontrolled illness including, but not limited to, 
ongoing or active infection (or infections requiring 
systemic antibiotic treatment), symptomatic congestive 
heart failure, unstable angina pectoris, cardiac 
arrhythmia, or psychiatric illness/social situations that 
would limit compliance with study requirem ents.         
6. Any concurrent malignancy other than non -melanoma 
skin cancer, non -invasive bladder cancer, or carcinoma in 
situ of the cervix.  Patients with a previous malignancy 
without evidence of disease for > 5 years will be allowed 
to enter the trial .    
7. Pregnant and breastfeeding women are excluded, as well 
as women of child -bearing potential who are unwilling or 
unable to use an acceptable method of birth control 
(hormonal or barrier method of birth control; abstinen ce) 
to avoid pregnancy for the duration of the study.  Male 
subjects must also agree to use effective contraception for 
the same period as above.          
8. Women who are not post -menopausal (as defined in 
Appendix III) and have a positive urine or serum 
pregnancy test or refuse to take a pregnancy test          
*Supporting documentation is required to confirm subject eligibility  and can include but is not limited to :  clinic 
notes, laboratory results, pathology results, radiology reports , subject self -report , or MD documentation .   
 
 
 
 
 
 Page 75 of 84 
  
 
    
IV.  Statement of Eligibility  
By signing this form of this trial I verify that this subject is [
eligible  / ineligible]  for participation in the 
study. This study is approved by the Stanford Cancer Institute Scientific Review Committee, the Stanford IRB, and has finalized financial and contractual agreements as required by Stanford School of Medicine’s Research Management Group. 
Study Coordinator Signature: Date: 
Printed Name: 
Secondary Reviewer Signature: Date: 
Printed Name: 
Treating Physician Signature: Date: 
Printed Name: 
 
 
 
    
 
    
  
Page 76 of 84 
  
 
Appendix V  
 
Case Report Form  and Patient Logs:  
 
 
 Case Report Form  for SAEs , AEs , and UPs  
 
 Subject Log  
 
 Protocol Deviation Log  
 
 AE ( Adverse Event ) Tracking Form  
 
 Page 77 of 84 
 
Received On:_______ ______  
Date Submitted to CCTO:______ _______  
Date Submitted to SUMC IRB:_______ ______  
 
Case Report Form for SAEs, AEs, and UPs 
 
Protocol:  Pancreatic Cancer Radiotherapy Study Group (PanCRS) Trial:   
A Randomized Phase III Study Evaluating Modified FOLFIRINOX (mFFX) with or without  
Stereotactic Body Radiotherapy (SBRT) in the Treatment of Locally Advanced Pancreatic Cancer 
 
Stanford eprotoco l #:__27492__     OnCore #:__PANC0015_ 
Date of Report: ___________ _______  
Participating Site and 
Location:_____________________________________________________  
 
Date of Event:________________________  
Subject’s Initials: _____________________    
Subject’s OnCore #:___________________  
Research Staff Completing Form: 
 
Name: ______ _______________ ___________________  
    
Phone: _____________________ ___________________  
 Email: ________________________________________  
Principal Investigator / Treating Physician at study site has reviewed and agrees with information in this report: 
Printed Name: _______________________________________  
 
 
Signature: ___________________________________________  Date: _________________  
  
Page 78 of 84 
  
 
 
 
Answer all questions below.  Provide ad ditional pages as needed .   
 
1. Check if event was :   
      
 Serious Adverse Event (SAE) *     
 Adverse Event (AE) *  
 Unanticipated Problem (UP) # 
  
 *Note  Grade : _   (According to CTCAE, V 4 or greater, available at  http://ctep.cancer.gov/reporting/ctc.html .) 
 
 #If also UP, check that it meets criteria  for:    
Unexpected  
    
 Related  
    
 Harmful   
 
 2. Check the box of which therapy the event was related or possibly related to:    
 
  mFOLFIRINOX    
 SBRT      
  Other, indicate: _____________________ _____   
     
3. Indicate how muc h treatment the subject received up to the event:  
 - For mFOLFIRINOX , Cycles_______  and Days  or Doses _______  
 - For SBRT, fractions______  and cGy_______  
 
4. Provide a brief description of the event, including:  
 symptoms reported and when (dates)  
 results o f scans, labs, or other procedures or tests  
 if hospital ED visit or admission, give dates and length of hospitalization  
 If Grade 5, indicate date of death, primary cause, if death certificate obtained, and if autopsy 
performed  
 
 __________________________ ___________________________________________________ ___
__ 
 _____________________________________________________________________________ ___
__ 
 _____________________________________________________________________________ ___
__ 
 ______________________________ _______________________________________________ ___
__ 
 _____________________________________________________________________________ ___
__ 
 
5. Following the event:   
 Was therapy discontinued?     
  No   
 Yes 
 N/A 
 Was dose modified?    
No        
Yes     
 N/A 
 If Yes, note modified dose(s): ________________________________________________ _____  
  
Page 79 of 84 
  _____________________________________________________________________________ ___
__ 
 
6. Define the action plan and follow -up, including:  
 Next visit and follow -up schedu le if not per protocol  
 Referrals for tests, procedures, specialty or other clinics  
 Other pertinent information:  
_____________________________________________________________________________ _____  
_____________________________________________________________ ________________ _____  
__________________________________________________________________________________  
 
Page 80 of 84              Protocol:  Pancreatic Cancer Radiotherapy Study Group (PanCRS) Trial:  A Randomized  
Phase III Study Evaluating Modified FOLFIRINOX (mFFX ) with or without Stereotactic Body  
Radiotherapy (SBRT) in the Treatment of Locally Advanced Pancreatic Cancer  
 
    Stanford eProtocol # :  27492     OnCore #:   PANC001 5     
 
 
  
Participating Center: ___________________________________________      
 
 
Subjec t Log  
  # Subject Name  Subject  
Initials  Subject ID or 
OnCore #  Date On -Study 
(Date of 
Randomization)  Treatment 
Arm  Treatment 
Start Date 
(Day 1)  Date  
Off-Study  Reason Off -Study  
1 
  
    mFFX  
 +SBRT   
    
2 
  
    mFFX  
 +SBRT   
    
3 
   
     mFFX  
 +SBRT   
    
4 
   
     mFFX  
 +SBRT   
    
5 
   
     mFFX  
 +SBRT   
    
6        
 mFFX  
 +SBRT       

  
Page 81 of 84 
 7        
 mFFX  
 +SBRT       
8        
 mFFX  
 +SBRT       
9        
 mFFX  
 +SBRT       
10        
 mFFX  
 +SBRT       
 
 
 
   
 Protocol:  Pancreatic Cancer Radiotherapy Study Group (PanCRS) 
Trial:  A Randomized Phase III Study       Evaluating Modified FOLFIRINOX (mFFX) with or without Stereotactic Body  
Radiotherap y (SBRT) in the Treatment of Locally Advanced Pancreatic Cancer  
 
    Stanford eProtocol # :  27492     OnCore #:   PANC0015         
 
 Participating Center: ___________________________________________      
 
Protocol Deviation Log  
# Subject 
Initials  Subject ID or  
OnCore #  Date of 
Deviation  Category (see 
next page) Code 
(see next 
page)  Brief Description  Date IRB 
notified, if 
applicable  Corrective Action  
1       
   
2       
   
3       
   
4       
   

  
Page 82 of 84 
 5       
   
6       
   
7       
   
8       
   
9       
   
10       
   
11       
   
12       
   
 
Deviation  Categories   
 
A.  Safety  
B.  Informed Consent   
C.  Eligibility  
D.  Protocol Implementation   
E.  Other, specify in log  
 
 
Deviation Codes  (associated with Deviation categories)  
 
  
Page 83 of 84 
  
Safety (Category A)  
1. Not repo rting SAE within 24 hours  
2. Laboratory tests not done  
3. AE/SAE not reported to IRB  
4. Other, specify on log  
 
 
Informed Consent  (Category B)  
5. Failure to obtain informed consent  
6. Consent form used was not current IRB approved 
version  
7. Consent form does not include up dates or information 
required by IRB  
8. Consent form missing  
9. Consent form not signed and dated by participant  
10. Consent form does not contain all required signatures  
11. Other, specify in log  
  
Eligibility (Category C)  
12. Participant did not meet eligibility criteria  
13. Randomization of an ineligible patient  
14. Participant randomized prior to Baseline Assessment  
15. Randomization or treatment of a patient prior to IRB approval 
of protocol  
16. Other, specify in log  
 
Protocol Implementation (category D)  
17. Failure to keep IRB approval up  to date  
18. Participant receives wrong treatment  
19. Participant seen outside of window visit  
20. Use of unallowable concomitant treatments  
21. Prescribed dosing outside of protocol guidelines  
22. Missed Assessment  
23. Missed Visit  
24. Other, specify in log  
 
 
 
Page 84 of 84 
 